Collaborative Testing Services, Inc
FORENSIC TESTING PROGRAM

P.O. Box 650820
Sterling, VA 20165-0820
e-mail: forensics@cts-interlab.com
Telephone: +1-571-434-1925
Web site: www.cts-forensics.com

Blood Drug Analysis
Test No. 20-5661 Summary Report

Each sample set contained blood samples from three cases along with the case scenario. Each case sample consisted of two vials containing human blood spiked with different drugs and/or metabolites. Participants were requested to examine these items and report their findings. Data were returned from 140 participants and are compiled into the following tables:

This report contains the data received from the participants in this test. Since these participants are located in many countries around the world, and it is their option how the samples are to be used (e.g., training exercise, known or blind proficiency testing, research and development of new techniques, etc.), the results compiled in the Summary Report are not intended to be an overview of the quality of work performed in the profession and cannot be interpreted as such. The Summary Comments are included for the benefit of participants to assist with maintaining or enhancing the quality of their results. These comments are not intended to reflect the general state of the art within the profession.

Participant results are reported using a randomly assigned "WebCode". This code maintains participant's anonymity, provides linking of the various report sections, and will change with every report.

Manufacturer's Information

Each sample set contained blood samples from three cases, each with an individual case scenario. Each case sample consisted of two grey-topped vials containing human blood. Participants were asked to analyze the blood samples and report the presence of any drugs/metabolites and quantitative data obtained (including uncertainty).

SAMPLE PREPARATION:
The human blood used in this test was from the same lot, which tested negative for a variety of common controlled substances prior to being obtained from a commercial supplier.

A stock solution of each drug was used to spike specific items. These solutions were obtained in sealed ampoules and were not opened until needed for production. Items were prepared at separate times using the following procedure.

ITEMS 1, 2, and 3 (PREPARATION):
Item preparation consisted of adding a predetermined amount of drug stock solution to human whole blood. It was stirred before pipetting the mixture into each of the pre-labeled vials, which contained Potassium Oxalate and Sodium Fluoride. The vials were sealed and inverted multiple times to mix the chemicals in the vials with the blood solution. All vials were placed in a refrigerator immediately after production and stored there until the sample sets were prepared.

SAMPLE SET ASSEMBLY:
Each sample set contained two vials of each of the three Items and placed into a Department of Transportation regulated shipping container. The sample packs were then returned to the refrigerator until shipment.

VERIFICATION:
All but one laboratory that conducted predistribution analysis of the samples reported consistent drug/metabolite identifications. There was one participant that did not report the presence of Lorazepam. The reported concentration results were comparable to the preparation drug concentrations with the exception of Item 3. Given the fact that Cocaine can be unstable, it was not unexpected to see a lower concentration reported for Cocaine and a higher concentration of Benzoylecgonine. This information is representative of a small number of laboratories, evaluation of results should be deferred until the Summary Report is published.

Item 1 Drug (Concentration)	Item 2 Drug (Concentration)	Item 3 Drug (Concentration)
Lorazepam (400 ng/mL)	Zolpidem (300 ng/mL)	Cocaine (800 ng/mL) Benzoylecgonine (640 ng/mL)

Please note that the preparation concentration is the value used for calculations during the test preparation phase and may not necessarily represent the final concentration of the samples. It is advised to wait for the Grand Mean statistics available in the Summary and Individual Reports before evaluating performance.

Summary Comments

This test was designed to allow participants to assess their proficiency in the examination for the presence and concentration of drugs and/or metabolites in blood. Each participant was supplied with two vials containing human blood spiked with different drugs and/or metabolites for each of three case scenarios. Participants were asked to report the presence of any drugs/metabolites, quantitative data obtained (including uncertainty), and methods used (Refer to the Manufacturer's Information for preparation details).

Of the 139 participants who reported screening results for Item 1, 133 participants (95.7%) reported drug(s) detected. All of these participants reported one or a combination of Lorazepam and Benzodiazepine. There were other responses reported by 10 of these 133 participants, which included 8 participants reporting additional drugs other than those listed above, and two participants that did not list a drug name/class or reported that analysis was not performed on the item. There were 128 participants that reported confirmatory analysis results for Item 1. The presence of Lorazepam was confirmed by 94.5% of participants, with one participant reporting the Benzodiazepine class. Six participants reported that there were no drugs/metabolites detected.

Of the 136 participants who reported screening results for Item 2, 110 participants (80.9%) reported drug(s) detected. Of the 110 participants who reported detection, 108 reported the presence of Zolpidem with only three participants reporting an additional substance present. Of the remaining two participants, one reported the Cannabinoids class only and the other reported drugs detected during screening but did not include a drug name or class. There were 123 participants that reported results for confirmatory analysis for Item 2. The presence of Zolpidem was confirmed by 97.6% of participants. Of these, one participant also reported the presence of another substance. Three participants reported no drugs/metabolites detected.

Of the 135 participants who reported screening results for Item 3, all but two reported drug(s) detected; 131 of these participants reported the presence of Cocaine and/or one of its metabolites. There were 127 participants that reported results for confirmatory analysis for Item 3. The presence of Cocaine was confirmed by 93.7% of participants, and the presence of Benzoylecgonine was confirmed by 80.3% of participants. Of the participants that confirmed the presence of cocaine and/or benzoylecgonine, 25 participants confirmed one or more additional cocaine metabolites.

If a participant indicated that the confirmatory quantitative result was a single determination and reported it in ng/mL, the conclusive quantitative result was included in the raw data table. The raw data was used to calculate the grand mean and standard deviation for each item and are supplied to assist the participants and accrediting bodies in determining the acceptability of results. There was one participant determined to have “extreme” data (±3 STD from grand mean) for Item 1 and Item 2. For Item 3, two participants were determined to have "extreme" data for Cocaine and three participants were determined to have “extreme” data for Benzoylecgonine. Due to the instability of Cocaine, it was not unexpected to see lower concentration values for Cocaine and higher concentration values for Benzoylecgonine than the sample preparation values. This may account for the extreme variations in the grand mean for these analytes.

Screening Results - Item 1

TABLE 1A: Item 1

Item Scenario:

A 71 year-old female was found unresponsive one morning by her daughter. The daughter mentioned that her mother was recently widowed and as a result, was feeling anxious and not sleeping well. Blood samples were collected at autopsy.

Item Contents and Preparation Concentration: Lorazepam (400 ng/mL)

Webcode	Screening Results
2ACRQF	Lorazepam
2E8LNG	Lorazepam
2EPH94	Benzodiazepines
2UG8AR	Benzodiazepines
2XJ9AP	Benzodiazepines
2YB6YJ	Benzodiazpines
3DN4Z2	No drugs/metabolites detected
3KCMK6	Cannabinoids Benzodiazepines
3KPCLW	Benzodiazepines
44YQHG	Benzodiazepines
4BYD8V	Benzodiazepines
4DPCNF	Benzodiazepines
4XTWNL	Benzodiazepines
629PCT	benzodiazepines, lorazepam
66889Z	Benzodiazepines group Lorazepam
6LRX8Y	Lorazepam
727GLK	Benzodiazepines
76GRCU	Lorazepam
7BRH4F	Benzodiazepine
7NHE4T	Benzodiazepines
7VEA3C	benzodiazepines
86YZ3A	Benzodiazepines
8ACPKX	benzodiazepines
8EL42W	Benzodiazepines
8EMV2P	lorazepam acetaminophen
8R99DY	Benzodiazepines
8VB7NR	benzodiazepines
8Z9QTB	Benzodiazepines
97CUGN	lorazepam and delta-9 THC

TABLE 1A: Item 1

Webcode	Screening Results
9RQG6E	Benzodiazepines
9Z4P7G	Lorazepam
AD4T2U	Lorazepam
APGREB	Lorazepam
B2QQLN	Benzodiazepines
B3FFJA	Benzodiazepine
B6P3HN	Benzodiazepines
BMATGN	lorazepam acetaminophen
CEATHL	lorazepam
CF3P4U	Benzodiazepines
CG2P7F	Benzodiazepines
CGDN2N	benzodiazapines
CLC3NE	Benzodiaepines
CVTQGR	Lorazepam
CWUJGK	Benzodiazepines
D2FWTT	Benzodiazepines
DB6MH7	Benzodiazepine
DCFLCE	Benzodiazepines
DE4XBK	Naproxen Lorazepam
DQLF7C	Benzodiazepines
DVT9XM	Lorazepam
E2DN47	Benzodiazepine
E7TWPJ	lorazepam
E9WUZC	Benzodiazepines
EBNQP7	[Participant reported that drugs were detected, but did not report the drug class or name]
EJEBTJ	lorazepam
EPJ8E6	Benzodiazepines
EVQXHB	lorazepam
EZLREC	Benzodiazepines
FGNPD2	Benzodiazepines
FLCGGN	Lorazepam
FLGT6K	Benzodiazepines
FZZBY9	Benzodiazepines
G4R6AF	Lorazepam
GHBM66	Lorazepam

TABLE 1A: Item 1

Webcode	Screening Results
GQTWT2	Lorazepam
HPRHKY	lorazepam
HQNYVB	Benzodiazepines, Lorazepam
HRVE42	Benzodiazepines Lorazepam
HU693M	Benzodiazepine group Lorazepam
HUNAQB	Benzodiazepines
J8N9E8	Benzodiazepine class
JMF7F3	Benzodiazepine class
K2UQD2	Benzodiazepines
KB6TY2	Benzodiazepines
KD9NH6	Benzodiazepines
KG9YE6	No drugs/metabolites detected
KMY9N3	benzodiazepines
KPYPTJ	lorazepam
KQAJEC	benzodiazepines
KQYHTD	Lorazepam
KRRDFL	Benzodiazepines
KWZWFZ	No drugs/metabolites detected
L2AAXX	Benzodiazepines
LCTQQ6	Benzodiazepine
LG7QMW	Benzodiazepines
LX9D7H	Benzodiazepines 1 , Benzodiazepines 2
MLCHP3	Benzodiazepines
N8QPEZ	No drugs/metabolites detected
NAX8DW	Lorazepam
NLB4HZ	Lorazepam
NW98LU	Benzodiazepines
NZRZXW	Benzodiazepines Lorazepam
PLRKB8	lorazepam
PN98MR	Benzodiazepines
QE2PNU	Benzodiazepine
QFHLGU	Benzodiazepines
QKPCJZ	Benzodiazepines
QQGJ29	Lorazepam, Caffeine, Naproxen
QW7W4W	Benzodiazepines

TABLE 1A: Item 1

Webcode	Screening Results
R4ZNPV	Benzodiazepines
RJRLQQ	Benzodiazepines
RNLFNR	Benzodiazepine
RTZY69	Benzodiazepines Acetaminophen
RXACM8	Lorazepam
T9PLQQ	No analysis carried out
TJN2UA	lorazepam
TR2B4N	Lorazepam
U89QNV	Benzodiazepines
UAZMDP	Lorazepam Sertraline
UHR3Z9	Benzodiazepines
ULU4Z7	Benzodiazepines
V6X936	Lorazepam
VCJ2E6	Benzodiazepines
VGTEXP	Lorazepam
VLAMK3	Benzodiazepines
VWMPYA	Benzodiazepines
VX37ZU	No drugs/metabolites detected
VXFV2L	Lorazepam
WD9MML	Lorazepam
WK9AC2	lorazepam
WZN8JM	Benzodiazepine
X2PRKR	Benzodiazepines presumptively positive
X69MMK	LORAZEPAM
XA9XJK	Benzodiazepines: LORAZEPAM.
XKMVNN	No drugs/metabolites detected
XTGZE4	Lorazepam
XXRDW3	Lorazepam
Y32RE2	Benzodiazepines
Y97MZL	Benzodiazepine Class
YFQNFY	Benzodiazepines
YKLHDZ	Benzodiazepines
YLWK2K	Benzodiazepines
Z6ZP3Y	Benzodiazepines
Z8QNGW	Lorazepam

TABLE 1A: Item 1

Webcode	Screening Results
ZAJJ6Q	Benzodiazepines
ZJ6NDQ	Benzodiazepines
ZJMUCG	Lorazepam (Benzodiacepine)
ZMZJU6	Benzodiazepines
ZUPRKP	Benzodiazepines

Item 1 - Response Summary	Participants Reporting Screening Results: 139
Lorazepam:	49
Benzodiazepines:	90
No drugs/metabolites detected:	6
*Other:	11

Participants can report multiple drugs/metabolites; therefore, the sum of the values here may be greater than the total number of participants responding for this item.

*This category represents the total number of participants that reported a response other than that which is listed above.

Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?

TABLE 1B: Item 1

Item Scenario:

A 71 year-old female was found unresponsive one morning by her daughter. The daughter mentioned that her mother was recently widowed and as a result, was feeling anxious and not sleeping well. Blood samples were collected at autopsy.

Item Contents and Preparation Concentration: Lorazepam (400 ng/mL)

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2ACRQF	Lorazepam		298.56	38.81	ng/mL
2EPH94	Lorazepam		583.1		ng/mL
2UG8AR	Lorazepam		335	67	ng/mL
2XJ9AP	Lorazepam		292	63	ng/ml
2YB6YJ	Lorazepam		0.32	+/-18%	ug/ml
3DN4Z2	No drugs/metabolites detected				
3KCMK6	Lorazepam		347	21.87%	ng/mL
44YQHG	Lorazepam	✓			
4BYD8V	Lorazepam	✓			
4DPCNF	Lorazepam		370	8.1	%
4XTWNL	No drugs/metabolites detected				
629PCT	lorazepam		0.26	0.08	mg/L
66889Z	lorazepam		0.32	0.050	mg/L
6LRX8Y	Lorazepam	✓			
76GRCU	Lorazepam	✓			
7BRH4F	Lorazepam	✓			
7NHE4T	Lorazepam		326	± 56	ng/mL
7VEA3C	lorazepam	✓			
86YZ3A	Lorazepam	✓			
8ACPKX	Lorazepam		390		ng/mL
8EL42W	Benzodiazepines	✓			
8EMV2P	lorazepam		0.35	0.11	mg/L
8R99DY	Lorazepam		434	21.87%	ng/mL
8VB7NR	lorazepam	✓			
	naproxen	✓			

TABLE 1B: Item 1

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
8Z9QTB	Lorazepam		414.02	27%	ug/L
97CUGN	lorazepam		0.35	0.11	mg/L
9RQG6E	Lorazepam		288	21.87%	ng/mL
9Z4P7G	Lorazepam	✓			
AD4T2U	Lorazepam	✓			
APGREB	Lorazepam	✓			
B2QQLN	Lorazepam		372	64	ng/mL
B3FFJA	Lorazepam	✓			
B6P3HN	Lorazepam		334	+/- 57	ng/mL
BMATGN	lorazepam		395	50	ng/mL
CEATHL	lorazepam		0.37	0.11	mg/L
CF3P4U	lorazepam		0.38	0.07	ug/mL
CG2P7F	Lorazepam		358	+/-78	ng/ml
CGDN2N	lorazepam		346		ng/mL
CLC3NE	Lorazepam		340	+/- 74	ng/ml
CVTQGR	Lorazepam		336.4	63.9	ng/mL
CWUJGK	Lorazepam	✓			
D2FWTT	lorazepam		0.35	±0.07	µg/ml
DB6MH7	Lorazepam		383.42	3.5	%
DCFLCE	Lorazepam		0.36	0.04	mg/L
DE4XBK	Lorazepam Naproxen		Approx. 0.3 Approx. 0.6		mg/L mg/L
DVT9XM	Lorazepam	✓			
E2DN47	Lorazepam Caffeine	✓ ✓			
E7TWPJ	lorazepam		300	80	ng/mL
E9WUZC	Lorazepam		343	+/-75	ng/mL
EBNQP7	Lorazepam	✓			
EJEBTJ	lorazepam		0.37	0.11	mg/L
EPJ8E6	Lorazepam		399	15	%
EVQXHB	lorazepam		351,9	50%	ng/mL
EZLREC	Lorazepam		283	+/- 62	ng/mL
FGNPD2	Lorazepam	✓			

TABLE 1B: Item 1

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
FLCGGN	Lorazepam	✓			
FLGT6K	Lorazepam	✓			
FZZBY9	No drugs/metabolites detected				
G4R6AF	Lorazepam		226	72	ng/mL
GHBM66	Lorazepam		340		ng/mL
GQTWT2	Lorazepam	✓			
HPRHKY	lorazepam		323		ng/mL
HQNYVB	Lorazepam		0.41	0.05	mg/L
HRVE42	Lorazepam	✓			
HU693M	lorazepam		0.33	0.051	mg/L
HUNAQB	Lorazepam	✓			
J8N9E8	Lorazepam		416	91	ng/mL
JMF7F3	Lorazepam	✓			
K2UQD2	Lorazepam	✓			
KB6TY2	Lorazepam	✓			
KD9NH6	No drugs/metabolites detected				
KG9YE6	No drugs/metabolites detected				
KMY9N3	lorazepam		376	21.87	ng/ml
KPYPTJ	lorazepam	✓			
KQYHTD	Lorazepam		0.39	0.12	mg/L
KRRDFL	Lorazepam		307	67	ng/mL
L2AAXX	Lorazepam	✓			
LCTQQ6	Lorazepam		289	+/- 63	ng/mL
LG7QMW	Lorazepam	✓			
LX9D7H	Lorazepam		0.22	+/- 0.09	ug/ml
MLCHP3	No drugs/metabolites detected				
NAX8DW	Lorazepam		402.9	13	ng/mL
NLB4HZ	Lorazepam		327 ng/mL	21.87%	ng/mL
NW98LU	Lorazepam		> 250		ng/mL
NZRZXW	Lorazepam	✓			
PLRKB8	lorazepam		0.33	0.10	mg/L
PN98MR	lorazepam	✓			

TABLE 1B: Item 1

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
QE2PNU	Lorazepam	✓			
QFHLGU	Lorazepam	✓			
QKPCJZ	Lorazepam		352	+/- 77	ng/mL
QQGJ29	Lorazepam		0.327	0.047	mg/L
	Caffeine	✓			
	Naproxen	✓			
QW7W4W	Lorazepam		406	21.87%	ng/mL
R4ZNPV	Lorazepam		330	21.87%	ng/mL
RJRLQQ	Lorazepam	✓			
RNLFNR	Lorazepam	✓			
RTZY69	Lorazepam	✓			
RXACM8	Lorazepam		379.35	75.87	ng/mL
TJN2UA	Lorazepam		369	70	ng/mL
TR2B4N	Lorazepam	✓			
U89QNV	Lorazepam		362	+/- 79	ng/mL
UAZMDP	Lorazepam	✓			
UHR3Z9	Lorazepam		0.37	0.07	µg/mL
ULU4Z7	Lorazepam	✓			
V6X936	Lorazepam	✓			
VCJ2E6	Lorazepam	✓			
VGTEXP	Lorazepam	✓			
VLAMK3	Lorazepam		250	38	ng/mL
VWMPYA	Lorazepam	✓			
VXFV2L	Lorazepam	✓			
WD9MML	Lorazepam	✓			
WK9AC2	lorazepam		0.31	+/- 0.09	mg/L
WMYBHP	Lorazepam	✓			
WZN8JM	Lorazepam		386	+/- 13%	ug/L
X2PRKR	Lorazepam		340	+/- 74	ng/mL
X69MMK	LORAZEPAM	✓			
XA9XJK	LORAZEPAM	✓			
XKMVNN	Lorazepam	✓			
XTGZE4	Lorazepam		362		ng/mL

TABLE 1B: Item 1

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
XXRDW3	Lorazepam		0.31	0.09	mg/L
Y32RE2	Lorazepam	✓			
Y97MZL	Lorazepam	✓			
YKLHDZ	lorazepam	✓			
YLWK2K	Lorazepam	✓			
Z6ZP3Y	Lorazepam	✓			
	Naproxen	✓			
Z8QNGW	Lorazepam		0.34	0.10	mg/L
ZAJJ6Q	Lorazepam		331	+/-72	ng/mL
ZJ6NDQ	Lorazepam		350	+/- 77	ng/ml
ZJMUCG	Lorazepam		0.350		mg/L

Item 1 - Response Summary **Participants Reporting Confirmatory Results: 128**

Lorazepam: 121

No drugs/metabolites detected: 6

*Other: 5

Participants can report multiple drugs/metabolites; therefore, the sum of the values here may be greater than the total number of participants responding for this item.

*This category represents the total number of participants that reported a response other than that which is listed above.

Raw Data - Item 1

List of raw data determinations in ng/mL.

TABLE 1C: Item 1

Item 1 Raw Data - Lorazepam

Preparation concentration: 400 ng/mL

Webcode	Raw Data (ng/mL)		Participant Mean	
2ACRQF	298.6		298.6	
2EPH94	583.1		583.1	X
2UG8AR	335.0		335.0	
2XJ9AP	292.0		292.0	
2YB6YJ	311.0	333.0	322.0	
3KCMK6	347.0		347.0	
4DPCNF	378.2	369.5	373.9	
629PCT	264.8		264.8	
66889Z	327.2		327.2	
7NHE4T	326.0		326.0	
8ACPKX	388.8		388.8	
8EMV2P	351.1		351.1	
8R99DY	434.0		434.0	
8Z9QTB	414.0	398.5	406.3	
97CUGN	351.2		351.2	
9RQG6E	288.8		288.8	
B2QQLN	372.0		372.0	
B6P3HN	334.0		334.0	
BMATGN	394.9	394.9	394.9	
CEATHL	370.2		370.2	
CF3P4U	383.7		383.7	
CG2P7F	358.0		358.0	
CGDN2N	346.0		346.0	
CLC3NE	340.0		340.0	
CVTQGR	336.4		336.4	
D2FWTT	359.0		359.0	
DB6MH7	383.4	387.9	385.7	
DCFLCE	359.5	358.5	359.0	

TABLE 1C: Item 1

Item 1 Raw Data - Lorazepam

Preparation concentration: 400 ng/mL

Webcode	Raw Data (ng/mL)						Participant Mean
DE4XBK	269.0	279.0					274.0
E7TWPJ	304.0	303.0	306.0				304.3
E9WUZC	343.0						343.0
EJEBTJ	373.0						373.0
EPJ8E6	399.0	429.0					414.0
EVQXHB	351.9						351.9
EZLREC	283.5						283.5
G4R6AF	226.4						226.4
GHBM66	354.0	325.0					339.5
HPRHKY	323.0						323.0
HQNYVB	389.0	384.0	434.0	419.0			406.5
HU693M	332.4						332.4
J8N9E8	416.0						416.0
KMY9N3	376.0						376.0
KQYHTD	392.2						392.2
KRRDFL	307.6						307.6
LCTQQ6	289.6						289.6
LX9D7H	250.8	186.4					218.6
NAX8DW	393.1	398.2	428.7	395.4	408.2	413.9	406.3
NLB4HZ	327.0						327.0
NW98LU	[No raw data reported]						
PLRKB8	327.2						327.2
QKPCJZ	352.5						352.5
QQGJ29	335.8	317.4					326.6
QW7W4W	406.0						406.0
R4ZNPV	330.2						330.2
RXACM8	[No raw data reported]						
TJN2UA	[No raw data reported]						
U89QNV	362.0						362.0
UHR3Z9	378.3						378.3
VLAMK3	250.7						250.7

TABLE 1C: Item 1

Item 1 Raw Data - Lorazepam

Preparation concentration: 400 ng/mL

Webcode	Raw Data (ng/mL)		Participant Mean
WK9AC2	310.1		310.1
WZN8JM	385.7		385.7
X2PRKR	340.0		340.0
XTGZE4	362.9		362.9
XXRDW3	309.5	304.5	307.0
Z8QNGW	342.3		342.3
ZAJJ6Q	331.0		331.0
ZJ6NDQ	350.0		350.0
ZJMUCG	[No raw data reported]		

Statistical Analysis for Item 1 - Lorazepam

Grand Mean:	343.1	Number of Participants Included:	63	Number of Participants without Raw Data or Data that was not reported in ng/mL:	4
Standard Deviation:	44.92	Number of Participants Excluded:	1		

TABLE 1C: Item 1

Item 1 Raw Data - Other

Webcode	Analyte	Raw Data (ng/mL)
DE4XBK	Naproxen	585.00

Statistical Analysis for Item 1 - Other

Please note statistical analysis has not been provided due to the low number of raw data responses.

Reporting Procedures - Item 1

If quantitative analysis was performed, the reported concentrations are:

TABLE 1D: Item 1

Webcode	Quantitative Reporting Procedures
2ACRQF	A single determination.
2EPH94	A single determination.
2UG8AR	A single determination.
2XJ9AP	A single determination.
2YB6YJ	The mean of duplicate/several determinations.
3KCMK6	A single determination.
4DPCNF	The mean of duplicate/several determinations.
4XTWNL	A single determination.
629PCT	A single determination.
66889Z	A single determination.
7NHE4T	A single determination.
8ACPKX	A single determination.
8EMV2P	A single determination.
8R99DY	A single determination.
8Z9QTB	A single determination.
97CUGN	A single determination.
9RQG6E	A single determination.
B2QQLN	A single determination.
B6P3HN	A single determination.
BMATGN	The mean of duplicate/several determinations.
CEATHL	A single determination.
CF3P4U	A single determination.
CG2P7F	A single determination.
CGDN2N	A single determination.
CLC3NE	A single determination.
CVTQGR	A single determination.
D2FWTT	A single determination.
DB6MH7	A single determination.
DCFLCE	The mean of duplicate/several determinations.

TABLE 1D: Item 1

Webcode	Quantitative Reporting Procedures
DE4XBK	Naproxen single determination, Lorazepam mean of duplicate determinations.
E7TWPJ	The mean of duplicate/several determinations.
E9WUZC	A single determination.
EJEBTJ	A single determination.
EPJ8E6	A single determination.
EVQXHB	A single determination.
EZLREC	A single determination.
FZZBY9	A single determination.
G4R6AF	A single determination.
GHBM66	The mean of duplicate/several determinations.
HPRHKY	A single determination.
HQNYVB	The mean of duplicate/several determinations.
HU693M	A single determination.
J8N9E8	A single determination.
KD9NH6	A single determination.
KMY9N3	A single determination.
KQYHTD	A single determination.
KRRDFL	A single determination.
LCTQQ6	A single determination.
LX9D7H	The mean of duplicate/several determinations.
MLCHP3	A single determination.
NAX8DW	The mean of duplicate/several determinations.
NLB4HZ	A single determination.
NW98LU	A single determination.
PLRKB8	A single determination.
QKPCJZ	A single determination.
QQGJ29	The mean of duplicate/several determinations.
QW7W4W	A single determination.
R4ZNPV	A single determination.
RXACM8	A single determination.
TJN2UA	A single determination.
U89QNV	A single determination.

TABLE 1D: Item 1

Webcode	Quantitative Reporting Procedures
UHR3Z9	A single determination.
VLAMK3	A single determination.
WK9AC2	A single determination.
WZN8JM	single determination confirmed by dilution
X2PRKR	A single determination.
XTGZE4	A single determination.
XXRDW3	The mean of duplicate/several determinations.
Z8QNGW	A single determination.
ZAJJ6Q	A single determination.
ZJ6NDQ	A single determination.
ZJMUCG	A single determination.

Response Summary for Item 1	Participants: 72
A single determination:	59 (81.9%)
The mean of duplicate/several determinations:	11 (15.3%)
Other:	2 (2.8%)

Methods of Analysis - Item 1

TABLE 1E: Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
2ACRQF	LC/MS/MS	✓	✓	✓
2EPH94	Immunoassay	✓		
	LC/MS/MS		✓	✓
2UG8AR	Immunoassay	✓		
	LC/MS/MS		✓	✓
2XJ9AP	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
2YB6YJ	Immunoassay	✓		
	LC/MS/MS		✓	✓
3DN4Z2	GC/MS		✓	
3KCMK6	LC/MS/MS		✓	✓
3KPCLW	Immunoassay	✓		
44YQHG	Immunoassay	✓		
	GC/MS		✓	
4BYD8V	Immunoassay	✓		
	GC/MS		✓	
	LC-QTOF-MS	✓	✓	
4DPCNF	Immunoassay	✓		
	GC/MS	✓	✓	✓
4XTWNL	Immunoassay	✓		
	LC/MS/MS		✓	
629PCT	LC/MS/MS	✓	✓	✓
	Immunoassay	✓		
66889Z	Immunoassay	✓		
	LC-TOF-MS	✓		
	LC/MS/MS		✓	✓
6LRX8Y	LC/MS/MS	✓	✓	
727GLK	Immunoassay	✓		
76GRCU	LC/MS/MS	✓	✓	
7BRH4F	Immunoassay	✓		
	GC/MS		✓	
7NHE4T	Immunoassay	✓		
	LC/MS/MS		✓	✓
7VEA3C	Immunoassay	✓		
	GC/MS		✓	
86YZ3A	Immunoassay	✓		
	LC/MS/MS		✓	
8ACPKX	Immunoassay	✓		
	LC/MS/MS		✓	✓
8EL42W	Immunoassay	✓		

TABLE 1E: Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
8EMV2P	LC-HRAMS	✓		
	LC/MS/MS		✓	✓
8R99DY	Immunoassay	✓		
	LC/MS/MS		✓	✓
8VB7NR	Immunoassay	✓		
	GC/MS		✓	
8Z9QTB	Immunoassay	✓		
	GC/MS		✓	✓
97CUGN	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
9RQG6E	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
9Z4P7G	LC/MS/MS	✓	✓	
AD4T2U	LC/QTOF	✓		
	GC/MS		✓	
APGREB	LC/MS/MS	✓		
	LC/MS/MS		✓	
B2QQLN	Immunoassay	✓		
	LC/MS/MS		✓	✓
B3FFJA	Immunoassay	✓		
	GC/MS	✓	✓	
B6P3HN	Immunoassay	✓		
	LC/MS/MS		✓	✓
BMATGN	LC/MS/MS		✓	✓
	QTOF screen	✓		
	Immunoassay	✓		
CEATHL	LC-HRMS/MS	✓		
	LC/MS		✓	✓
CF3P4U	Immunoassay	✓		
	LC/MS/MS		✓	✓
CG2P7F	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
CGDN2N	Immunoassay	✓		
	LC/MS/MS		✓	✓
CLC3NE	Immunoassay	✓		
	LC/MS/MS		✓	✓
CVTQGR	LC/MS/MS	✓	✓	✓
CWUJGK	Immunoassay	✓		
	GC/MS		✓	
D2FWTT	Immunoassay	✓		
	LC/MS/MS		✓	✓
DB6MH7	GC/MS		✓	
	Immunoassay	✓		

TABLE 1E: Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
DCFLCE	Immunoassay	✓		
	LC/MS		✓	
	LC/MS/MS			✓
DE4XBK	Immunoassay	✓		
	LC/MS/MS		✓	✓
	HPLC-DAD	✓		✓
	LC/MS	✓	✓	
DQLF7C	Immunoassay	✓		
DVT9XM	LC/MS/MS	✓	✓	
E2DN47	Immunoassay	✓		
	LC/MS/MS		✓	
E7TWPJ	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	LC-TOFMS	✓		
E9WUZC	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS	✓		
	GC/FID	✓		
EBNQP7	LC/MS/MS		✓	
EJEBTJ	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	GC/MS		✓	
EPJ8E6	Immunoassay	✓		
	GC/MS	✓	✓	✓
EVQXHB	GC/MS	✓	✓	✓
	LC/MS/MS	✓	✓	
EZLREC	Immunoassay	✓		
	GC/MS		✓	
	GC/FID			✓
	LC/MS/MS		✓	✓
FGNPD2	Immunoassay	✓		
	GC/MS		✓	
FLCGGN	LC/MS/MS	✓	✓	
FLGT6K	Immunoassay	✓		
	LC-QTOF-MS	✓	✓	
	GC/MS		✓	
FZZBY9	Immunoassay	✓		
	LC/MS/MS		✓	✓
G4R6AF	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS	✓	✓	✓
GHBM66	LC/MS/MS	✓		
	LC-HRMS	✓	✓	
	LC/MS			✓
GQTWT2	GC/MS		✓	

TABLE 1E: Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
HPRHKY	LC/MS/MS	✓		
	GC/MS		✓	
HQNYVB	Immunoassay	✓		
	LC/MS/MS		✓	✓
	LC-QTOF	✓	✓	
HRVE42	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	
	LC/QTOF-MS	✓		
HU693M	Immunoassay	✓		
	LC-TOF-MS	✓		
	LC/MS/MS		✓	✓
HUNAQB	Immunoassay	✓		
	LC/MS/MS		✓	
J8N9E8	Immunoassay	✓		
	LC/MS/MS		✓	✓
JMF7F3	Immunoassay	✓		
	GC/MS	✓	✓	
K2UQD2	Immunoassay	✓		
	GC/MS		✓	
KB6TY2	Immunoassay	✓		
	GC/MS		✓	
KD9NH6	Immunoassay	✓		
	LC/MS/MS		✓	✓
KG9YE6	Immunoassay	✓		
	GC/MS	✓	✓	
KMY9N3	Immunoassay	✓		
	LC/MS/MS		✓	✓
KPYPTJ	LC/MS/MS	✓	✓	
KQAJEC	Immunoassay	✓		
KQYHTD	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
KRRDFL	Immunoassay	✓		
	LC/MS/MS		✓	✓
KWZWFZ	Immunoassay	✓		
L2AAXX	Immunoassay	✓		
	GC/MS	✓	✓	
LCTQQ6	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
LG7QMW	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
LX9D7H	Immunoassay	✓		
	LC/MS - QTOF		✓	✓

TABLE 1E: Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
MLCHP3	Immunoassay	✓		
	LC/MS/MS		✓	✓
N8QPEZ	LC/MS/MS	✓	✓	
NAX8DW	LC/MS	✓		✓
	LC/MS/MS		✓	
NLB4HZ	Immunoassay	✓		
	LC/MS/MS		✓	✓
NW98LU	Immunoassay	✓		
	LC/MS/MS		✓	✓
NZRZXW	Immunoassay	✓		
	GC/MS	✓		
	LC/QTOF-MS	✓		
	LC/MS/MS		✓	
PLRKB8	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
PN98MR	Immunoassay	✓		
	GC/MS		✓	
QE2PNU	Immunoassay	✓		
	GC/MS		✓	
QFHLGU	Immunoassay	✓		
	GC/MS	✓	✓	
QKPCJZ	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	✓
	GC/FID	✓		
QQGJ29	LC/MS/MS		✓	✓
	Immunoassay	✓		
	LC QTOF	✓	✓	
QW7W4W	Immunoassay	✓		
	LC/MS/MS		✓	✓
R4ZNPV	Immunoassay	✓		
	LC/MS/MS		✓	✓
RJRLQQ	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
RNLFNR	Immunoassay	✓		
	GC/MS		✓	
RTZY69	QTOF screening	✓	✓	
	Immunoassay	✓		
	GC/MS		✓	
RXACM8	LC/MS/MS	✓	✓	✓
TJN2UA	GC/MS	✓		
	LC/MS/MS	✓	✓	✓
TR2B4N	GC/MS		✓	

TABLE 1E: Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
U89QNV	Immunoassay	✓		
	GC/MS-FID	✓		
	LC/MS/MS		✓	✓
UAZMDP	LC/MS/MS	✓	✓	
UHR3Z9	Immunoassay	✓		
	LC/MS/MS		✓	✓
ULU4Z7	Immunoassay	✓		
	GC/MS	✓		
	LC-QTOF MS		✓	
V6X936	LC/MS/MS	✓	✓	
VCJ2E6	Immunoassay	✓		
	LC-QTOFMS		✓	
	GC/MS	✓		
VGTEXP	GC/MS	✓		
	LC/MS/MS	✓	✓	
VLAMK3	Immunoassay	✓		
	UPLC-QTOF MS	✓		
	LC/MS/MS			✓
VWMPYA	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
VX37ZU	LC/MS/MS	✓	✓	
VXFV2L	LC/MS/MS	✓	✓	
WD9MML	Immunoassay	✓		
	GC/MS		✓	
WK9AC2	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
WMYBHP	GC/MS		✓	
WZN8JM	Immunoassay	✓		
	GC/MS	✓	✓	✓
X2PRKR	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
	GC/FID		✓	
X69MMK	LC/MS	✓		
	LC/MS/MS		✓	
XA9XJK	GC/MS	✓		
	LC/MS/MS		✓	
XKMVNN	GC/MS		✓	
XTGZE4	LC/MS/MS	✓		
	GC/MS		✓	✓
XXRDW3	LC/MS/MS	✓	✓	✓
	Immunoassay	✓		

TABLE 1E: Item 1

Webcode	Method	Screening	Confirmatory	Quantitation
Y32RE2	Immunoassay	✓		
	GC/MS		✓	
	LC-MS-QTOF		✓	
Y97MZL	Immunoassay	✓		
	GC/MS	✓	✓	
YFQNFY	Immunoassay	✓		
	LC/MS/MS	✓		
YKLHDZ	Immunoassay	✓		
	GC/MS		✓	
YLWK2K	Immunoassay	✓		
	GC/MS	✓	✓	
Z6ZP3Y	Immunoassay	✓		
	GC/MS		✓	
Z8QNGW	LC-HR-MS/MS	✓	✓	
	LC/MS/MS		✓	✓
ZAJJ6Q	Immunoassay	✓		
	LC/MS/MS		✓	✓
ZJ6NDQ	Immunoassay	✓		
	LC/MS/MS		✓	✓
ZJMUCG	Immunoassay	✓		
	HPLC-DAD			✓
	GC/MS		✓	
ZMZJU6	Immunoassay	✓		
ZUPRKP	Immunoassay	✓		

Response Summary for Item 1 **Participants: 138**

	Screening	Confirmatory	Quantitation
Immunoassay:	99	0	0
GC/MS:	21	50	6
LC/MS:	3	3	3
LC/MS/MS:	27	83	58
Other:	25	12	4

Additional Comments for Item 1

TABLE 1F: Item 1

Webcode	Item 1 - Comments
2UG8AR	Internal Standard: Lorazepam-d4, LOD/LOQ: 5.0 ng/mL
2YB6YJ	Not tested for Lorazepam metabolites, Limit of Detection = 5 ng/ml
3KCMK6	No cannabinoids present.
3KPCLW	ELISA was used to screen the sample. The sample was screened using Immunalysis kits for Opiates, Benzodiazepines, PCP, Cocaine/BE, Cannabinoids and Methamphetamine.
44YQHG	Phenyltoloxamine (IRM) - Base fraction. Heptabarbital (IRM) - Acid fraction
4BYD8V	Codeine-indicated not reported GCMS and LC-QTOF-MS, internal standard: Mepivacaine
4XTWNL	Analysis by high performance liquid chromatography/tandem mass spectrometry in whole blood for: Analyte -Quantitative Range (ng/mL): Delta-9-THC- 0.5 – 50, 11-hydroxy-Delta-9-THC - 0.5 – 50, 11-nor-9-carboxy-Delta-9-THC - 5.0 - 500. Analysis by immunoassay screening in whole blood for:Assay- Cutoff* (ng/mL): Meth /Amphetamines- 20, Barbiturates -50, Benzodiazepines -10, Buprenorphine -5, Cannabinoids -10, Benzoylecgonine -50, Dextromethorphan -5, Fentanyl -1, Meprobamate -100, Methadone -10, Opiates -10, Opioids -10, Phencyclidine -5, TCA -25, Tramadol -5, Zolpidem -10. * Results within 20% of these concentrations are reported as preliminarily positive.
629PCT	internal standard: mepivacaine, diazepam-d5
727GLK	Benzodiazepines assay cutoff: 20 ng/mL
76GRCU	Limit of detection: 5 ng/mL, Internal standard: Clonazepam-D4
7BRH4F	Promazine - ISTD for Drug Screen. Prazepam - ISTD for Benzodiazepines
7NHE4T	The ELISA immunoassay was used to screen for six classes of drugs: amphetamines, benzodiazepines, cannabinoids, cocaine, opiates and PCP. The benzodiazepines analysis was performed on the LC/MS/MS. The cut off/limit of detection is 10 ng/mL. The internal standard used for Lorazepam was Lorazepam-d4. The compounds were extracted by solid phase extraction targeting free, non-conjugated/ non-protein bound compounds.
86YZ3A	Lorazepam: Internal standard = D5-Diazepam, LOD = 5.0 ng/mL.
8EL42W	Only Screening analysis was able to be performed by the laboratory.
8EMV2P	Negative for acetaminophen
8Z9QTB	The internal standard used in quantitation was d4-Lorazepam. The quantitative range used in this analysis was 20-500 ug/L.
97CUGN	diazepam d-5 is the internal standard used to quantitate lorazepam.
B2QQLN	1) This specimen screened negative for the following assays: cannabinoids, cocaine/metabolites, amphetamines, opiates, and phencyclidine. 2) The specimen was 'none detected' for the following compounds: oxazepam, alpha-hydroxyalprazolam, nordiazepam, alprazolam, clonazepam, and diazepam. 3) The cutoff for lorazepam is 10ng/mL. 4) The internal standard used for lorazepam is lorazepam-d4.
B6P3HN	ELISA was used to screen the sample. The sample was screened using Immunalysis kits for Opiates, Benzodiazepines, PCP, Cocaine/BE, Cannabinoids and Methamphetamine. Lorazepam-D4 was used as an internal standard with a limit of detection of 10 ng/mL.

TABLE 1F: Item 1

Webcode	Item 1 - Comments
BMATGN	low cut off for acetaminophen is 0.3 mg/L
CEATHL	Internal standard: diazepam-d5
CF3P4U	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Benzodiazapine confirmation/quantitation panel includes: alprazolam, diazepam, 7-aminoclonazepam, clonazepam, lorazepam, nordiazepam, oxazepam, and temazepam. The following internal standards are used: 7-aminoclonazepam D-4, alprazolam D-5, diazepam D-5, clonazepam D-4, nordiazepam D-5, oxazepam D-5, and temazepam D-5. LOD for all benzodiazapines quantitated is 5 ng/mL. LOQ for all benzodiazapines quantitated is 10 ng/mL.
CG2P7F	Used a 1:10 dilution, used 100ul of sample combined with 900ul of bank blood.
D2FWTT	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Benzodiazepine confirmation panel includes alprazolam, diazepam, 7-aminoclonazepam, clonazepam, lorazepam, nordiazepam, oxazepam and temazepam. LOD for the panel is 5ng/ml. LOQ for the panel is 10ng/ml. Oxazepam-D5 used as internal standard for lorazepam quantitation. Laboratory does not routinely analyze postmortem samples (outside scope of testing).
DCFLCE	The LC/MS used for confirmation was an LC/QTOF.
DE4XBK	The method LC/MS above [Table 1E: Methods of Analysis] was actually LC-QTOF-MS. There was no option to manually enter more than one method.
DQLF7C	Our lab currently doesn't have a method to confirm/quantitation benzodiazepines.
DVT9XM	Lorazepam calibration curve was limited 5-100ng/mL on the confirmatory testing. This compound is reported qualitative only in accordance with the SOP. LOD for lorazepam is 5ng/mL.
EBNQP7	D5-Diazepam used as Internal Standard.
EZLREC	Mepivacaine IS
FGNPD2	Used D4-Lorazepam as internal standard.
FLCGGN	Internal Standard: Clonazepam-D4. Lorazepam is qualitative only
FLGT6K	Immunoassay screen run 10/23/2020; Mepivacaine used as internal standard for LC-QTOF-MS and GC-MS
FZZBY9	Immunoassay cutoff concentrations (ng/mL): Meth /Amphetamines 20, Barbiturates 50, Benzodiazepines 10, Buprenorphine 5, Cannabinoids 10, Benzoylecgonine 50, Dextromethorphan 5, Fentanyl 1, Meprobamate 100, Methadone 10, Opiates 10, Opioids 10, Phencyclidine 5, TCA 25, Tramadol 5, Zolpidem 10, LC/MS/MS analysis ranges: Delta-9-THC 0.5 – 50, 11-hydroxy-Delta-9-THC 0.5 – 50, 11-nor-9-carboxy-Delta-9-THC 5.0 - 500.
HQNYVB	LC-QTOF internal standards: Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, Triazolam-D4. LC/MS/MS internal standard: Nordiazepam-D5.
HUNAQB	Lorazepam D4 IS, Lorazepam reporting limit 10ng/mL
JMF7F3	Prazepam utilized as ISTD for benzodiazepine confirmation. Promazine utilized as ISTD for GC/MS screening.
K2UQD2	Hexobarbital and Phenyltoloxamine were used as internal standards.

TABLE 1F: Item 1

Webcode	Item 1 - Comments
KD9NH6	Analysis by high performance liquid chromatography/tandem mass spectrometry in whole blood for: Analyte (Range). Delta-9-THC (0.5 – 50), 11-hydroxy-Delta-9-THC (0.5 – 50), 11-nor-9-carboxy-Delta-9-THC (5.0 - 500), Analysis by immunoassay screening in whole blood for: Analyte (Cutoff), Meth /Amphetamines (20), Barbiturates (50), Benzodiazepines (10), Buprenorphine (5), Cannabinoids (10), Benzoylecgonine (50), Dextromethorphan (5), Fentanyl (1), Meprobamate (100), Methadone (10), Opiates (10), Opioids (10), Phencyclidine (5), TCA (25), Tramadol (5), Zolpidem (10).
KQAJEC	confirmatory analysis not performed
KQYHTD	Mepivacaine internal standard used in screening method. Diazepam-d5 internal standard used in confirmatory/confirmation method. LOD = 6.25 ng/mL
L2AAXX	Drug Screen for Blood: Promazine ISTD used. Benzodiazepine Confirmation: 30uL Prazepam ISTD (20ug/mL) used.
LG7QMW	Confirmatory ISTD for GC/MS: NPA and SKF Confirmatory ISTD for LC/MS/MS: Prazepam-d5
LX9D7H	Immunoassay by Randox analyzer
MLCHP3	Analyte- Cutoff: Meth /Amphetamines -20, Barbiturates -50, Benzodiazepines -10, Buprenorphine -5, Cannabinoids -10, Benzoylecgonine -50, Dextromethorphan -5, Fentanyl -1, Meprobamate -100, Methadone -10, Opiates -10, Opioids -10, Phencyclidine -5, TCA -25, Tramadol -5, Zolpidem -10. LC/MS/MS confirmation for Cannabinoids- Analyte: Quantitative Range: Delta-9-THC: 0.5 – 50, 11-hydroxy-Delta-9-THC: 0.5 – 50, 11-nor-9-carboxy-Delta-9-THC : 5.0 - 500.
NLB4HZ	Original test >LOQ. Diluted since it was a reported death case.
NW98LU	Our benzodiazepine method has an upper limit of quantitation (ULOQ) of 250 ng/mL. The lorazepam result for item #1 was greater than 250 ng/mL, therefore this result would have been reported as "greater than 250 ng/mL of lorazepam was detected by LC/MS/MS."
PLRKB8	Internal standards used- diazepam-d5
PN98MR	ISTD = D4-Lorazepam
QE2PNU	Phenyltoloxamine IRM (base fraction), Heptabarbital IRM (acid fraction)
QFHLGU	Prazepam was used as an internal standard for the Benzodiazepine confirmation on GC/MS. Promazine was used as an internal standard for general drug screen test on GC/MS.
QW7W4W	Result reported from 1:2 dilution.
R4ZNPV	The original LC/MS/MS extraction was above the limit of quantitation. Because this case involved a death, a dilution of 1:10 was performed.
RJRLQQ	Confirmatory ISTD for GC/MS: NPA and SKF. Confirmatory ISTD for LC/MS/MS: Prazepam-d5
RTZY69	The QTOF screen is also used as a confirmatory method. Acetaminophen was screened in the QTOF screen but was not confirmed. Mepivacaine is the internal standard for the QTOF Screen and the GCMS method. Trace amounts of Etizolam and Isonitazene were seen but did not meet acceptance criteria for reporting.
U89QNV	The sample was ran at a 1:10 dilution for the benzodiazepine analysis in order to quantify the Lorazepam. The calibration curve went from 15ng/mL to 250ng/mL.

TABLE 1F: Item 1

Webcode	Item 1 - Comments
UHR3Z9	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Benzodiazepine confirmation/quantitation panel includes 7-aminoclonazepam, alprazolam, clonazepam, diazepam, lorazepam, nordiazepam, oxazepam, and temazepam. 7-aminoclonazepam-D4, alprazolam-D5, clonazepam-D4, diazepam-D5, noroxazepam-D5, oxazepam-D5, and temazepam-D5 used as internal standards. LOD for all benzodiazepines is 5 ng/mL; LOQ is 10 ng/mL. Laboratory does not routinely analyze postmortem samples.
ULU4Z7	Internal Standard - Mepivacaine
VCJ2E6	Internal Standard - Mepivacaine
VLAMK3	Screening: Immunoassay and UPLC-QTOF MS (Waters). For UPLC-QTOF MS (Waters): - Salting-out assisted extraction. - Internal Standards: Cyclobarbitone, Prazepam & D3-Methadone Lorazepam Quantitative Analysis - Instrument: UPLC-TQD (Waters) - Internal Standard: D5-Diazepam - LOD for Lorazepam: 5 ng/mL.
VWMPYA	Diazepam D5 was used as internal standard
WK9AC2	internal standards: mepivacaine,mephobarital = LC-HRMS/MS, diazepam-d5 = LC/MS/MS, limit of report: for lorazepam is 6.25 μg/L
X2PRKR	GC-MS and GC-FID were performed. No basic drugs were found; lorazepam is not analyzed using these techniques in our laboratory. LC/MS/MS was performed to confirm and quantitate the Lorazepam. Internal standard used was Diazepam-D5.
X69MMK	THE INTERNAL STANDARD USED WAS ESTAZOLAM.
XA9XJK	Internal standard: flurazepam, LoD: 10 ng/mL. The lab does not perform analysis of THC in blood.
XKMVNN	Lorazepam LOD 75 ng/mL. Internal standard: flurazepam.
XTGZE4	Lorazepam-D4 was used as the internal standard. Reporting range for calibration was 20ng/mL to 400ng/mL.
XXRDW3	Mepivacaine and/or diazepam-d5 used as internal standard in LC/MS/MS methods; limit of report for lorazepam is 6.25 mcg/L for quant method
Y97MZL	Promazine - Internal Standard for Butyl Acetate Screen. Prazepam - Internal Standard for Benzodiazepine Confirmation
YFQNFY	No additional testing performed.
YKLHDZ	internal standard: Lorazepam-D4-diTBDMS, limit of detection lorazepam: 5 ng/mL.
YLWK2K	Internal standard used for GC/MS drug screen was Promazine. Internal standard used for Benzodiazepine confirmation was Prazepam.
Z6ZP3Y	D4-Lorazepam-diTBDMS was used as the ISTD for Lorazepam. There is no screening method for Naproxen. It was found in a GC/MS extraction. Barbital was used as the ISTD for Naproxen.
Z8QNGW	Diazepam-d5 used as internal standard
ZMZJU6	Only Screening Testing performed.
ZUPRKP	Our lab does not currently have a confirmatory method for benzodiazepines.

Screening Results - Item 2

TABLE 2A: Item 2

Item Scenario:

A 28 year-old male was pulled over for a broken tail light. The officer noticed that the driver appeared drowsy and lethargic. A Drug Recognition Expert arrived and noted that the individual exhibited ataxia and loss of coordination. The result of a breath alcohol test was 0.00%. Blood was collected 60 minutes later.

Item Contents and Preparation Concentration: Zolpidem (300 ng/mL)

Webcode	Screening Results
2ACRQF	Zolpidem
2E8LNG	zolpidem
2EPH94	Zolpidum
2UG8AR	Zolpidem
2XJ9AP	No drugs/metabolites detected
3KCMK6	Cannabinoids
3KPCLW	No drugs/metabolites detected
44YQHG	Zolpidem
4BYD8V	Zolpidem
4DPCNF	Zolpidem
4XTWNL	Zolpidem
629PCT	zolpidem
66889Z	Zolpidem
6LRX8Y	Zolpidem
727GLK	Zolpidem
76GRCU	Zolpidem
7BRH4F	Zolpidem
7NHE4T	No drugs/metabolites detected
7VEA3C	zolpidem
86YZ3A	Zolpidem
8ACPKX	Zolpidem
8EL42W	No drugs/metabolites detected
8EMV2P	zolpidem acetaminophen delta 9 THC
8R99DY	Zolpidem
8VB7NR	zolpidem
8Z9QTB	Zolpidem
97CUGN	zolpidem
9RQG6E	No drugs/metabolites detected
9Z4P7G	Zolpidem

TABLE 2A: Item 2

Webcode	Screening Results
AD4T2U	Zolpidem
APGREB	zolpidem
B2QQLN	No drugs/metabolites detected
B3FFJA	Zolpidem
B6P3HN	No drugs/metabolites detected
BMATGN	Zolpidem
CEATHL	zolpidem
CF3P4U	zolpidem
CG2P7F	No drugs/metabolites detected
CGDN2N	zolpidem
CLC3NE	No drugs/metabolites detected
CVTQGR	Zolpidem
CWUJGK	Zolpidem
D2FWTT	Zolpidem
DB6MH7	No drugs/metabolites detected
DCFLCE	No drugs/metabolites detected
DE4XBK	Zolpidem
DQLF7C	Zolpidem
DVT9XM	Zolpidem
E2DN47	Zolpidem
E7TWPJ	Zolpidem
E9WUZC	Zolpidem
EBNQP7	[Participant reported that drugs were detected, but did not report the drug class or name]
EJEBTJ	zolpidem
EPJ8E6	Zolpidem
EVQXHB	zolpidem
EZLREC	No drugs/metabolites detected
FGNPD2	Zolpidem
FLCGGN	Zolpidem
FLGT6K	Zolpidem
FZZBY9	Zolpidem
G4R6AF	Zolpidem
GHBM66	Zolpidem
GQTWT2	Zolpidem
HPRHKY	zolpidem
HQNYVB	Zolpidem

TABLE 2A: Item 2

Webcode	Screening Results
HRVE42	Zolpidem
HU693M	Zolpidem
HUNAQB	Zolpidem
J8N9E8	No drugs/metabolites detected
JMF7F3	Zolpidem
K2UQD2	Zolpidem
KB6TY2	Zolpidem
KD9NH6	Zolpidem
KG9YE6	No drugs/metabolites detected
KMY9N3	zolpidem
KPYPTJ	zolpidem
KQAJEC	zolpidem
KQYHTD	Zolpidem
KRRDFL	No drugs/metabolites detected
KWZWFZ	Zolidem
L2AAXX	Zolpidem
LCTQQ6	No drugs/metabolites detected
LG7QMW	Zolpidem
LX9D7H	Zolpidem
MLCHP3	Zolpidem
N8QPEZ	Zolpidem
NAX8DW	Zolpidem
NLB4HZ	Zolpidem
NW98LU	Zolpidem
NZRZXW	Zolpidem
PLRKB8	zolpidem
PN98MR	zolpidem
QE2PNU	Zolpidem
QFHLGU	Zolpidem
QKPCJZ	Zolpidem
QQGJ29	Caffeine, Naproxen, Zolpidem
QW7W4W	No drugs/metabolites detected
R4ZNPV	Zolpidem
RJRLQQ	Zolpidem
RNLFNR	No drugs/metabolites detected

TABLE 2A: Item 2

Webcode	Screening Results
RTZY69	Immunoassay: None LC-QTOF-MS: Zolpidem
RXACM8	Zolpidem
T9PLQQ	Zolpidem
TJN2UA	Zolpidem
TR2B4N	No drugs/metabolites detected
U89QNV	No drugs/metabolites detected
UAZMDP	Zolpidem Sertraline
UHR3Z9	Zolpidem
ULU4Z7	Zolpidem
V6X936	zolpidem
VGTEXP	Zolpidem
VLAMK3	Zolpiderm
VWMPYA	No drugs/metabolites detected
VX37ZU	Zolpidem
VXFV2L	Zolpidem
WD9MML	Zolpidem
WK9AC2	zolpidem
WZN8JM	zolpidem
X2PRKR	No drugs/metabolites detected
X69MMK	ZOLPIDEM
XA9XJK	Nonbenzodiazepine hypnotics (z-drugs): ZOLPIDEM.
XKMVNN	No drugs/metabolites detected
XTGZE4	Zolpidem
XXRDW3	Zolpidem
Y32RE2	Zolpidem
Y97MZL	Zolpidem
YFQNFY	Zolpidem
YKLHDZ	zolpidem
YLWK2K	Zolpidem
Z6ZP3Y	Zolpidem
Z8QNGW	Zolpidem
ZAJJ6Q	No drugs/metabolites detected
ZJ6NDQ	No drugs/metabolites detected
ZJMUCG	Zolpidem (Hypnotic)
ZMZJU6	No drugs/metabolites detected

TABLE 2A: Item 2

Webcode	Screening Results
ZUPRKP	Zolpidem

Item 2 - Response Summary	Participants Reporting Screening Results: 136
Zolpidem:	108
No drugs/metabolites detected:	26
*Other:	7

Participants can report multiple drugs/metabolites; therefore, the sum of the values here may be greater than the total number of participants responding for this item.

*This category represents the total number of participants that reported a response other than that which is listed above.

Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?

TABLE 2B: Item 2

Item Scenario:

A 28 year-old male was pulled over for a broken tail light. The officer noticed that the driver appeared drowsy and lethargic. A Drug Recognition Expert arrived and noted that the individual exhibited ataxia and loss of coordination. The result of a breath alcohol test was 0.00%. Blood was collected 60 minutes later.

Item Contents and Preparation Concentration: Zolpidem (300 ng/mL)

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2ACRQF	Zolpidem		248.37	24.83	ng/mL
2E8LNG	Zolpidem	✓			
2EPH94	Zolpidum	✓			
2UG8AR	Zolpidem		288	58	ng/mL
2XJ9AP	Zolpidem		305	53	ng/ml
3DN4Z2	No drugs/metabolites detected				
3KCMK6	Zolpidem		>250ng/mL		ng/mL
44YQHG	Zolpidem	✓			
4BYD8V	Zolpidem	✓			
4DPCNF	Zolpidem		320	13	%
629PCT	zolpidem		0.31	0.09	mg/L
66889Z	Zolpidem		0.28	0.055	mg/L
6LRX8Y	Zolpidem		277	86	ng/mL
76GRCU	Zolpidem		304.54	+/-18	percent
7BRH4F	Zolpidem	✓			
7VEA3C	zolpidem	✓			
86YZ3A	Zolpidem		0.28	26%	ug/mL
8ACPKX	Zolpidem		320		ng/mL
8EMV2P	zolpidem		0.29	0.09	mg/L
8R99DY	Zolpidem		Greater than 250		ng/mL
8VB7NR	zolpidem	✓			
8Z9QTB	Zolpidem	✓			
97CUGN	zolpidem		0.33	0.10	mg/L
9RQG6E	Zolpidem		347	17.66%	ng/mL

TABLE 2B: Item 2

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
9Z4P7G	Zolpidem	✓			
AD4T2U	Zolpidem	✓			
APGREB	zolpidem	✓			
B3FFJA	Zolpidem	✓			
BMATGN	zolpidem		0.33	0.03	mg/L
CEATHL	zolpidem		0.31	0.09	mg/L
CF3P4U	zolpidem		0.28	0.04	ug/mL
CG2P7F	Zolpidem		347	+/-61	ng/ml
CGDN2N	zolpidem		241		ng/mL
CLC3NE	Zolpidem		242	+/- 43	ng/ml
CVTQGR	Zolpidem		309.7	68.1	ng/mL
CWUJGK	Zolpidem		298	27	ng/mL
D2FWTT	zolpidem		0.28	±0.05	µg/ml
DB6MH7	Zolpidem	✓			
DCFLCE	Zolpidem		0.31	0.03	mg/L
DE4XBK	Zolpidem		Approx. 0.3		mg/L
DVT9XM	Zolpidem		294.14	18	percent
E2DN47	Zolpidem	✓			
E7TWPJ	Zolpidem		300		ng/mL
E9WUZC	Zolpidem		331	+/-58	ng/mL
EBNQP7	Zolpidem	✓			
EJEBTJ	zolpidem		0.31	0.09	mg/L
EPJ8E6	Zolpidem	✓			
EVQXHB	zolpidem		276,50	30%	ng/ml
EZLREC	Zolpidem		285	+/- 50	ng/mL
FGNPD2	Zolpidem	✓			
FLCGGN	Zolpidem		243	75	ng/mL
FLGT6K	Zolpidem	✓			
G4R6AF	Zolpidem		238	76	ng/mL
GHBM66	Zolpidem		298		ng/mL
GQTWT2	Zolpidem	✓			

TABLE 2B: Item 2

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
HPRHKY	zolpidem	✓			
HQNYVB	Zolpidem		0.31	0.03	mg/L
HRVE42	Zolpidem	✓			
HU693M	Zolpidem		0.32	0.063	mg/L
HUNAQB	Zolpidem	✓			
J8N9E8	Zolpidem		280	49	ng/mL
JMF7F3	Zolpidem	✓			
K2UQD2	Zolpidem	✓			
KB6TY2	Zolpidem	✓			
KG9YE6	Zolpidem	✓			
KMY9N3	zolpidem		>250		ng/ml
KPYPTJ	zolpidem	✓			
KQYHTD	Zolpidem		0.32	0.10	mg/L
KRRDFL	Zolpidem		> 250		ng/mL
KWZWFZ	Zolpidem		295	38	ng/mL
L2AAXX	Zolpidem	✓			
LCTQQ6	Zolpidem		334	+/- 59	ng/mL
LG7QMW	Zolpidem	✓			
LX9D7H	Zolpidem		0.29	+/- 0.11	ug/ml
N8QPEZ	Zolpidem		240.89	38.54	ng/ml
NAX8DW	Zolpidem		241.4	1.3	ng/mL
NLB4HZ	Zolpidem		Greater than 250ng/mL		
NW98LU	Zolpidem		> 200		ng/mL
NZRZXW	Zolpidem	✓			
PLRKB8	zolpidem		0.31	0.09	mg/L
PN98MR	zolpidem	✓			
QE2PNU	Zollpidem	✓			
QFHLGU	Zolpidem	✓			
QKPCJZ	Zolpidem		284	+/- 50	ng/mL
QQGJ29	Zolpidem		0.291	0.036	mg/L
	Caffeine	✓			
	Naproxen	✓			

TABLE 2B: Item 2

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
QW7W4W	Zolpidem		>250		ng/mL
R4ZNPV	Zolpidem		Greater than 250		ng/mL
RJRLQQ	Zolpidem	✓			
RNLFNR	Zolpidem	✓			
RTZY69	Zolpidem	✓			
RXACM8	Zolpidem		322.82	64.57	ng/mL
T9PLQQ	Zolpidem		0.28	N/A	mg/L
TJN2UA	Zolpidem		297	44	ng/mL
TR2B4N	No drugs/metabolites detected				
U89QNV	Zolpidem		234	+/-41	ng/mL
UAZMDP	Zolpidem		285.4 ng/mL		
UHR3Z9	Zolpidem		0.28	0.04	µg/mL
ULU4Z7	Zolpidem	✓			
V6X936	zolpidem		272.47		ng/ml
VGTEXP	Zolpidem	✓			
VLAMK3	Zolpiderm		380	100	ng/mL
VWMPYA	Zolpidem	✓			
VX37ZU	Zolpidem		245.29	39.24	ng/mL
VXFV2L	Zolpidem	✓			
WD9MML	Zolpidem	✓			
WK9AC2	zolpidem		0.31	+/- 0.09	mg/L
WMYBHP	Zolpidem	✓			
WZN8JM	zolpidem	✓			
X2PRKR	Zolpidem		267	+/- 47	ng/mL
X69MMK	ZOLPIDEM	✓			
XA9XJK	ZOLPIDEM	✓			
XKMVNN	No drugs/metabolites detected				
XTGZE4	Zolpidem	✓			
XXRDW3	Zolpidem		0.34	0.10	mg/L
Y32RE2	Zolpidem	✓			
Y97MZL	Zolpidem	✓			

TABLE 2B: Item 2

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
YKLHDZ	zolpidem	✓			
YLWK2K	Zolpidem	✓			
Z6ZP3Y	Zolpidem	✓			
Z8QNGW	Zolpidem		0.35	0.11	mg/L
ZAJJ6Q	Zolpidem		266	+/-47	ng/mL
ZJ6NDQ	Zolpidem		351	+/- 62	ng/ml
ZJMUCG	Zolpidem		0.270		mg/L

Item 2 - Response Summary **Participants Reporting Confirmatory Results: 123**

Zolpidem:	120
No drugs/metabolites detected:	3
*Other:	1

Participants can report multiple drugs/metabolites; therefore, the sum of the values here may be greater than the total number of participants responding for this item.

*This category represents the total number of participants that reported a response other than that which is listed above.

Raw Data - Item 2

List of raw data determinations in ng/mL.

TABLE 2C: Item 2

Item 2 Raw Data - Zolpidem
Preparation concentration: 300 ng/mL

Webcode	Raw Data (ng/mL)				Participant Mean
2ACRQF	248.4				248.4
2UG8AR	288.0				288.0
2XJ9AP	305.5				305.5
3KCMK6	280.0				280.0
4DPCNF	305.2	328.8			317.0
629PCT	310.6				310.6
66889Z	285.5				285.5
6LRX8Y	277.0				277.0
76GRCU	304.5				304.5
86YZ3A	283.6				283.6
8ACPKX	319.3				319.3
8EMV2P	286.0				286.0
8R99DY	286.0				286.0
97CUGN	334.0				334.0
9RQG6E	347.9				347.9
BMATGN	332.6	323.5	328.2	322.2	326.6
CEATHL	306.0				306.0
CF3P4U	283.1				283.1
CG2P7F	347.0				347.0
CGDN2N	241.0				241.0
CLC3NE	242.0				242.0
CVTQGR	309.7				309.7
CWUJGK	295.1	300.7			297.9
D2FWTT	286.1				286.1
DCFLCE	312.5	311.5			312.0
DE4XBK	287.0	297.0	291.0	300.0	293.8
DVT9XM	294.1				294.1
E7TWPJ	312.0	301.0	289.0		300.7

TABLE 2C: Item 2

Item 2 Raw Data - Zolpidem
Preparation concentration: 300 ng/mL

Webcode	Raw Data (ng/mL)						Participant Mean
E9WUZC	331.0						331.0
EJEBTJ	306.0						306.0
EVQXHB	276.5						276.5
EZLREC	285.0						285.0
FLCGGN	243.0						243.0
G4R6AF	238.5						238.5
GHBM66	319.0	276.0					297.5
HQNYVB	308.0	311.0	313.0	313.0			311.3
HU693M	327.6						327.6
J8N9E8	280.0						280.0
KMY9N3	294.0						294.0
KQYHTD	318.0						318.0
KRRDFL	[No raw data reported]						
KWZWFZ	[No raw data reported]						
LCTQQ6	334.2						334.2
LX9D7H	330.3	253.3					291.8
N8QPEZ	248.3	240.9					244.6
NAX8DW	242.3	240.7	244.0	241.0	241.2	239.7	241.5
NLB4HZ	[No raw data reported]						
NW98LU	[No raw data reported]						
PLRKB8	306.0						306.0
QKPCJZ	284.0						284.0
QQGJ29	305.1	277.3					291.2
QW7W4W	276.0						276.0
R4ZNPV	319.9						319.9
RXACM8	[No raw data reported]						
T9PLQQ	[No raw data reported]						
TJN2UA	[No raw data reported]						
U89QNV	234.0						234.0
UAZMDP	[No raw data reported]						

TABLE 2C: Item 2

Item 2 Raw Data - Zolpidem

Preparation concentration: 300 ng/mL

Webcode	Raw Data (ng/mL)		Participant Mean
UHR3Z9	284.1		284.1
V6X936	272.5		272.5
VLAMK3	375.0		375.0
VX37ZU	245.3		245.3
WK9AC2	312.0		312.0
X2PRKR	267.0		267.0
XXRDW3	347.8	339.3	343.5
Z8QNGW	352.2		352.2
ZAJJ6Q	266.0		266.0
ZJ6NDQ	351.0		351.0
ZJMUCG	[No raw data reported]		

Statistical Analysis for Item 2 - Zolpidem

Grand Mean:	295.2	Number of Participants Included:	60	Number of Participants without Raw Data or Data that was not reported in ng/mL:	9
Standard Deviation:	32.22	Number of Participants Excluded:	0		

Reporting Procedures - Item 2

If quantitative analysis was performed, the reported concentrations are:

TABLE 2D: Item 2

Webcode	Quantitative Reporting Procedures
2ACRQF	A single determination.
2EPH94	A single determination.
2UG8AR	A single determination.
2XJ9AP	A single determination.
3KCMK6	A single determination.
4DPCNF	The mean of duplicate/several determinations.
629PCT	A single determination.
66889Z	A single determination.
6LRX8Y	A single determination.
76GRCU	A single determination.
86YZ3A	A single determination.
8ACPKX	A single determination.
8EMV2P	A single determination.
8R99DY	A single determination.
97CUGN	A single determination.
9RQG6E	A single determination.
B2QQLN	None
BMATGN	The mean of duplicate/several determinations.
CEATHL	A single determination.
CF3P4U	A single determination.
CG2P7F	A single determination.
CGDN2N	A single determination.
CLC3NE	A single determination.
CVTQGR	A single determination.
CWUJGK	The mean of duplicate/several determinations.
D2FWTT	A single determination.
DCFLCE	The mean of duplicate/several determinations.
DE4XBK	The mean of duplicate/several determinations.
DVT9XM	A single determination.

TABLE 2D: Item 2

Webcode	Quantitative Reporting Procedures
E7TWPJ	The mean of duplicate/several determinations.
E9WUZC	A single determination.
EJEBTJ	A single determination.
EVQXHB	A single determination.
EZLREC	A single determination.
FLCGGN	A single determination.
G4R6AF	A single determination.
GHBM66	The mean of duplicate/several determinations.
HPRHKY	A single determination.
HQNYVB	The mean of duplicate/several determinations.
HU693M	A single determination.
J8N9E8	A single determination.
KMY9N3	A single determination.
KQYHTD	A single determination.
KRRDFL	A single determination.
KWZWFZ	A single determination.
LCTQQ6	A single determination.
LX9D7H	The mean of duplicate/several determinations.
N8QPEZ	Sample was screened and confirmed on a quantitative method, the lower of the two values is the reported concentration
NAX8DW	The mean of duplicate/several determinations.
NLB4HZ	A single determination.
NW98LU	A single determination.
PLRKB8	A single determination.
QKPCJZ	A single determination.
QQGJ29	The mean of duplicate/several determinations.
QW7W4W	A single determination.
R4ZNPV	A single determination.
RXACM8	A single determination.
T9PLQQ	The mean of duplicate/several determinations.
TJN2UA	A single determination.
U89QNV	A single determination.

TABLE 2D: Item 2

Webcode	Quantitative Reporting Procedures
UAZMDP	A single determination.
UHR3Z9	A single determination.
V6X936	A single determination.
VLAMK3	A single determination.
VX37ZU	Sample was screened and confirmed on a quantitative method, the lower of the two values is the reported concentration
WK9AC2	A single determination.
X2PRKR	A single determination.
XXRDW3	The mean of duplicate/several determinations.
Z8QNGW	A single determination.
ZAJJ6Q	A single determination.
ZJ6NDQ	A single determination.
ZJMUCG	A single determination.

Response Summary for Item 2	Participants: 72
A single determination:	56 (77.8%)
The mean of duplicate/several determinations:	13 (18.1%)
Other:	3 (4.2%)

Methods of Analysis - Item 2

TABLE 2E: Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
2ACRQF	LC/MS/MS	✓	✓	✓
2E8LNG	GC/MS	✓	✓	
2EPH94	Immunoassay	✓		
	LC/MS/MS		✓	
2UG8AR	Immunoassay	✓		
	LC/MS/MS		✓	✓
2XJ9AP	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
3DN4Z2	GC/MS		✓	
3KCMK6	LC/MS/MS		✓	✓
3KPCLW	Immunoassay	✓		
44YQHG	Immunoassay	✓		
	GC/MS		✓	
4BYD8V	Immunoassay	✓		
	GC/MS		✓	
	LC-QTOF-MS	✓		
4DPCNF	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/NPD			✓
4XTWNL	Immunoassay	✓		
629PCT	LC/MS/MS	✓	✓	✓
66889Z	LC-TOF-MS	✓		
	LC/MS		✓	✓
6LRX8Y	LC/MS/MS	✓	✓	✓
727GLK	Immunoassay	✓		
76GRCU	LC/MS/MS	✓	✓	✓
7BRH4F	Immunoassay	✓		
	GC/MS	✓	✓	
7NHE4T	Immunoassay	✓		
7VEA3C	GC/MS	✓	✓	
	Immunoassay	✓		
86YZ3A	GC/NPD &/or MS	✓	✓	✓
8ACPKX	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
8EL42W	Immunoassay	✓		
8EMV2P	LC-HRAMS	✓		
	LC/MS/MS		✓	✓
8R99DY	GC/MS	✓		
	LC/MS/MS		✓	✓

TABLE 2E: Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
8VB7NR	Immunoassay	✓		
	GC/MS		✓	
8Z9QTB	Immunoassay	✓		
	GC/MS		✓	
97CUGN	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
9RQG6E	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
9Z4P7G	LC/MS/MS	✓	✓	
AD4T2U	LC/QTOF	✓		
	GC/MS		✓	
APGREB	LC/MS/MS	✓		
	LC/MS/MS		✓	
B2QQLN	Immunoassay	✓		
B3FFJA	GC/MS	✓	✓	
B6P3HN	Immunoassay	✓		
BMATGN	LC/MS/MS		✓	✓
	Immunoassay	✓		
	QTOF	✓		
CEATHL	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
CF3P4U	Immunoassay	✓		
	LC/MS/MS		✓	✓
CG2P7F	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
CGDN2N	Immunoassay	✓		
	LC/MS/MS		✓	✓
CLC3NE	Immunoassay	✓		
	LC/MS/MS		✓	✓
CVTQGR	LC/MS/MS	✓	✓	✓
CWUJGK	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS			✓
D2FWTT	Immunoassay	✓		
	LC/MS/MS		✓	✓
DB6MH7	Immunoassay	✓		
	GC/MS		✓	
DCFLCE	Immunoassay	✓		
	LC/MS		✓	
	LC/MS/MS			✓
DE4XBK	Immunoassay	✓		
	LC/MS/MS		✓	✓
	HPLC-DAD	✓		✓
	LC/MS	✓	✓	

TABLE 2E: Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
DQLF7C	Immunoassay	✓		
DVT9XM	LC/MS/MS	✓	✓	✓
E2DN47	Immunoassay	✓		
	LC/MS/MS		✓	
E7TWPJ	LC-TOFMS	✓		
	LC/MS/MS	✓	✓	✓
E9WUZC	LC/MS/MS		✓	✓
	Immunoassay	✓		
	GC/MS	✓		
	GC/FID	✓		
EBNQP7	LC/MS/MS		✓	
EJEBTJ	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	GC/MS		✓	
EPJ8E6	Immunoassay	✓		
	GC/MS	✓	✓	
EVQXHB	GC/MS	✓	✓	✓
	LC/MS/MS	✓	✓	
EZLREC	Immunoassay	✓		
	GC/MS		✓	
	GC/FID			✓
	LC/MS/MS		✓	✓
FGNPD2	Immunoassay	✓		
	GC/MS		✓	
FLCGGN	LC/MS/MS	✓	✓	✓
FLGT6K	Immunoassay	✓		
	LC-QTOF	✓		
	GC/MS		✓	
FZZBY9	Immunoassay	✓		
G4R6AF	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS	✓	✓	✓
GHBM66	LC/MS/MS	✓		
	LC-HRMS	✓	✓	
	LC/MS			✓
GQTWT2	GC/MS		✓	
HPRHKY	LC/MS/MS	✓		
	GC/MS		✓	
HQNYVB	Immunoassay	✓		
	LC-QTOF	✓		
	LC/MS/MS		✓	✓
HRVE42	Immunoassay	✓		
	GC/MS		✓	
	LC/QTOF-MS	✓		
HU693M	LC-TOF-MS	✓		
	LC/MS		✓	✓

TABLE 2E: Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
HUNAQB	Immunoassay	✓		
	GC/MS		✓	
J8N9E8	Immunoassay	✓		
	LC/MS/MS		✓	✓
JMF7F3	Immunoassay	✓		
	GC/MS	✓	✓	
K2UQD2	Immunoassay	✓		
	GC/MS		✓	
KB6TY2	Immunoassay	✓		
	GC/MS		✓	
KD9NH6	Immunoassay	✓		
KG9YE6	Immunoassay	✓		
	GC/MS	✓	✓	
KMY9N3	GC/MS	✓		
	LC/MS/MS		✓	✓
KPYPTJ	LC/MS/MS	✓	✓	
KQAJEC	Immunoassay	✓		
KQYHTD	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
KRRDFL	GC/MS	✓		
	LC/MS/MS		✓	✓
KWZWFZ	Immunoassay	✓		
	GC/MS		✓	✓
L2AAXX	Immunoassay	✓		
	GC/MS	✓	✓	
LCTQQ6	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
LG7QMW	Immunoassay	✓		
	GC/MS		✓	
LX9D7H	Immunoassay	✓		
	LC/MS - QTOF		✓	✓
MLCHP3	Immunoassay	✓		
N8QPEZ	LC/MS/MS	✓	✓	✓
NAX8DW	LC/MS	✓		✓
	LC/MS/MS		✓	
NLB4HZ	GC/MS	✓		
	LC/MS/MS		✓	✓
NW98LU	Immunoassay	✓		
	LC/MS/MS		✓	✓
NZRZXW	Immunoassay	✓		
	LC/QTOF-MS	✓		
	GC/MS		✓	
PLRKB8	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓

TABLE 2E: Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
PN98MR	Immunoassay	✓		
	GC/MS		✓	
QE2PNU	Immunoassay	✓		
	GC/MS		✓	
QFHLGU	Immunoassay	✓		
	GC/MS	✓	✓	
QKPCJZ	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	✓
	GC/FID	✓		
QQGJ29	Immunoassay	✓		
	LC/MS/MS		✓	✓
	LC QTOF	✓	✓	
QW7W4W	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	✓
R4ZNPV	GC/MS	✓		
	LC/MS/MS		✓	✓
RJRLQQ	Immunoassay	✓		
	GC/MS		✓	
RNLFNR	Immunoassay	✓		
	GC/MS	✓	✓	
RTZY69	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
RXACM8	LC/MS/MS	✓	✓	✓
T9PLQQ	LC/MS Orbitrap HRMS	✓		
	LC/MS/MS			✓
TJN2UA	GC/MS	✓		
	LC/MS/MS	✓	✓	✓
TR2B4N	GC/MS		✓	
U89QNV	Immunoassay	✓		
	GC/MS-FID	✓		
	LC/MS/MS		✓	✓
UAZMDP	LC/MS/MS	✓	✓	✓
UHR3Z9	Immunoassay	✓		
	LC/MS/MS		✓	✓
ULU4Z7	Immunoassay	✓		
	GC/MS		✓	
	LC-QTOF-MS	✓		
V6X936	LC/MS/MS	✓	✓	
VGTEXP	GC/MS	✓		
	LC/MS/MS	✓	✓	
VLAMK3	UPLC-QTOF MS	✓	✓	✓

TABLE 2E: Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
VWMPYA	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
VX37ZU	LC/MS/MS	✓	✓	✓
VXFV2L	LC/MS/MS	✓	✓	
WD9MML	Immunoassay	✓		
	GC/MS	✓	✓	
WK9AC2	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
WMYBHP	GC/MS		✓	
WZN8JM	Immunoassay	✓		
	GC/MS	✓	✓	
X2PRKR	Immunoassay	✓		
	GC/MS		✓	
	GC/FID		✓	
	LC/MS/MS		✓	✓
X69MMK	LC/MS	✓		
	LC/MS/MS		✓	
XA9XJK	GC/MS	✓		
	LC/MS/MS		✓	
XKMVNN	GC/MS		✓	
XTGZE4	LC/MS/MS	✓		
	GC/MS		✓	
XXRDW3	LC/MS/MS	✓	✓	✓
Y32RE2	Immunoassay	✓		
	GC/MS		✓	
	LC-MS-QTOF	✓		
Y97MZL	Immunoassay	✓		
	GC/MS	✓	✓	
YFQNFY	Immunoassay	✓		
	LC/MS/MS	✓		
YKLHDZ	Immunoassay	✓		
	GC/MS		✓	
YLWK2K	Immunoassay	✓		
	GC/MS	✓	✓	
Z6ZP3Y	Immunoassay	✓		
	GC/MS		✓	
Z8QNGW	LC-HR-MS/MS	✓	✓	
	LC/MS/MS		✓	✓
ZAJJ6Q	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	✓
ZJ6NDQ	Immunoassay	✓		
	LC/MS/MS		✓	✓

TABLE 2E: Item 2

Webcode	Method	Screening	Confirmatory	Quantitation
ZJMUCG	HPLC-DAD	✓		✓
	GC/MS		✓	
ZMZJU6	Immunoassay	✓		
ZUPRKP	Immunoassay	✓		

Response Summary for Item 2 **Participants: 138**

	Screening	Confirmatory	Quantitation
Immunoassay:	83	0	0
GC/MS:	30	57	2
LC/MS:	3	4	4
LC/MS/MS:	27	68	57
Other:	30	7	7

Additional Comments for Item 2

TABLE 2F: Item 2

Webcode	Item 2 - Comments
2UG8AR	Internal Standard: Zolpidem-d6, LOD/LOQ: 10.0 ng/mL
3KCMK6	No cannabinoids present. Sample can not be accurately quantitated beyond 250ng/mL.
3KPCLW	ELISA was used to screen the sample. The sample was screened using Immunalysis kits for Opiates, Benzodiazepines, PCP, Cocaine/BE, Cannabinoids and Methamphetamine.
44YQHG	Phenyltoloxamine (IRM) - Base fraction. Heptabarbital (IRM) - Acid fraction
4BYD8V	Acetaminophen indicated- not reported. GCMS and LC-QTOF-MS internal standard: Mepivacaine
4XTWNL	Assay- Cutoff* (ng/mL): Meth /Amphetamines- 20, Barbiturates -50, Benzodiazepines -10, Buprenorphine -5, Cannabinoids -10, Benzoylecgonine -50, Dextromethorphan -5, Fentanyl -1, Meprobamate -100, Methadone -10, Opiates -10, Opioids -10, Phencyclidine -5, TCA -25, Tramadol -5, Zolpidem -10.
629PCT	internal standard: mepivacaine
727GLK	Zolpidem assay cutoff: 10 ng/mL
76GRCU	Limit of detection: 5 ng/mL, Internal standard: Zolpidem-D6, Uncertainty of measurement range is: 249.73 ng/mL - 359.35 ng/mL
7BRH4F	Promazine - ISTD for Drug Screen
7NHE4T	The ELISA immunoassay was used to screen for six classes of drugs: amphetamines, benzodiazepines, cannabinoids, cocaine, opiates and PCP.
86YZ3A	Zolpidem: Internal standard = Carbinoxamine, LOD = 0.10 ug/mL.
8EL42W	Only Screening analysis was able to be performed by the laboratory.
8EMV2P	Negative for acetaminophen and delta 9 THC
97CUGN	Mepivacaine is the internal standard used to quantitate zolpidem.
B2QQLN	1) This specimen screened negative for the following assays: benzodiazepines, cannabinoids, cocaine/metabolites, amphetamines, opiates, and phencyclidine. 2) No confirmation was attempted due to the negative screen.
B6P3HN	ELISA was used to screen the sample. The sample was screened using Immunalysis kits for Opiates, Benzodiazepines, PCP, Cocaine/BE, Cannabinoids and Methamphetamine.
CEATHL	internal standard: mepivacaine
CF3P4U	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Confirmation/quantitation of zolpidem using zolpidem D-7 as internal standard. LOD for zolpiden is 5 ng/mL. LOQ for zolpidem is 10 ng/mL.
CG2P7F	Used a 1:10 dilution used 100ul of sample combined with 900ul of bank blood.
D2FWTT	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Confirmation/quantitation of zolpidem performed using zolpidem-D7 as internal standard. LOD is 5ng/ml. LOQ is 10ng/ml.
DCFLCE	The LC/MS used for confirmatory test was an LC/QTOF.
DE4XBK	The method listed as LC/MS above [Table 1E: Methods of Analysis] was actually LC-QTOF-MS.
DQLF7C	Our lab currently doesn't have a method to confirm/quantitation zolpidem.

TABLE 2F: Item 2

Webcode	Item 2 - Comments
DVT9XM	Calibration curve for zolpidem is 5-1000ng/mL. LOD for zolpidem in the confirmation method is 5ng/mL. Uncertainty range of the calculated concentration would be 241.19 ng/mL to 347.09 ng/mL.
E7TWPJ	Note this result would be reported as approximate as we have no uncertainty of measurement
EZLREC	Mepivacaine IS
FGNPD2	Used SKF-525A as internal standard.
FLCGGN	Internal Standard - Zolpidem-D6. Calibration Curve ranges from 10 - 1000 ng/mL
FLGT6K	Internal Standard used: Mepivacaine. Zolpidem Limit of Detection = 2.5 ng/mL in LC-QTOF
FZZBY9	Immunoassay cutoff concentrations (ng/mL): Meth /Amphetamines 20, Barbiturates 50, Benzodiazepines 10, Buprenorphine 5, Cannabinoids 10, Benzoylecgonine 50, Dextromethorphan 5, Fentanyl 1, Meprobamate 100, Methadone 10, Opiates 10, Opioids 10, Phencyclidine 5, TCA 25, Tramadol 5, Zolpidem 10.
GQTWT2	The identification was made by Libraria. For real cases, it must be compared with the respective reference material.
HQNYVB	LC-QTOF internal standards: Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, Triazolam-D4. LC/MS/MS internal standard: Zolpidem-D6.
HUNAQB	Prazepam (IS), Zolpidem reporting limit is 10ng/mL
JMF7F3	Promazine utilized as ISTD for GC/MS screening and GC/MS confirmatory tests.
K2UQD2	Phenyltoloxamine and Hexobarbital used as internal standards.
KD9NH6	Analysis by immunoassay screening in whole blood for: Analyte (Cutoff): Meth /Amphetamines (20), Barbiturates (50), Benzodiazepines (10), Buprenorphine (5), Cannabinoids (10), Benzoylecgonine (50), Dextromethorphan (5), Fentanyl (1), Meprobamate (100), Methadone (10), Opiates (10), Opioids (10), Phencyclidine (5), TCA (25), Tramadol (5), Zolpidem (10).
KQAJEC	confirmatory analysis not performed
KQYHTD	Mepivacaine internal standard used for both screening and confirmatory/quantitation methods. LOD = 25 ng/mL
KWZWFZ	Zolpidem, lower reporting limit (LRL) is 10 ng/mL. Zolpidem, limit of detection (LOD) is 10 ng/mL. Zolpidem, upper limit of linearity (ULOL) is 500 ng/mL.
L2AAXX	Drug Screen for Blood: Promazine ISTD used.
LG7QMW	Confirmatory ISTD for GC/MS: NPA and SKF
LX9D7H	Immunoassay by Randox analyzer
MLCHP3	Analyte- Cutoff: Meth /Amphetamines -20, Barbiturates -50, Benzodiazepines -10, Buprenorphine -5, Cannabinoids -10, Benzoylecgonine -50, Dextromethorphan -5, Fentanyl -1, Meprobamate -100, Methadone -10, Opiates -10, Opioids -10, Phencyclidine -5, TCA -25, Tramadol -5, Zolpidem -10.
N8QPEZ	LOQ: 5ng/ml; ISTD: Zolpidem-D6
NLB4HZ	>LOQ. Not diluted as this was not a death investigation.
NW98LU	Our zolpidem method has an upper limit of quantitation (ULOQ) of 200 ng/mL. The zolpidem result for item #2 was greater than 200 ng/mL, therefore this result would have been reported as "greater than 200 ng/mL of zolpidem was detected by LC/MS/MS."
PLRKB8	Internal standard used-mepivacaine
PN98MR	ISTD = SKF-525A
QE2PNU	Phenyltoloxamine IRM (base fraction), Heptabarbital IRM (acid fraction)

TABLE 2F: Item 2

Webcode	Item 2 - Comments
QFHLGU	Promazine was used as an internal standard for general drug screen tests (screen and confirmation) on GC/MS.
R4ZNPV	The zolpidem result is above the limit of quantitation. Because this is a DUI case, the results were reported as greater than 250 ng/mL and no measurement of uncertainty was included.
RJRLQQ	Confirmatory ISTD for GC/MS: NPA and SKF
RTZY69	Internal standards used: Mepivacaine, Nalorphine. Indications of Acetaminophen, Carbinoxamine, Cocaine, and Sertraline
T9PLQQ	[From Table 2- Raw Data: Listing of raw data not used in statistical calculations "Item 2: Zolpidem-0.2806, 0.2918]. Internal standard Zolpidem-d6, Limit of Quantitation - 0.01mg/L. Zolpidem is a hypnotic drug used in the treatment of insomnia. Side effects include daytime drowsiness, dizziness and amnesia which can adversely affect the performance of skilled tasks such as driving. Patients taking zolpidem are normally advised not to drive if they are affected in this way and preparations containing zolpidem are usually dispensed with a warning label, specified in the [Country] National Formulary, which reads: Warning: This medicine makes you sleepy. If you still feel sleepy the next day, do not drive or use tools or machines. Do not drink alcohol. The concentration of zolpidem found in the blood of the accused lies withinthe range of values found following the normal medical use of this drug.
UHR3Z9	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a positive zolpidem screen, confirmation/quantitation of zolpidem performed using zolpidem-D7 as internal standard. LOD for zolpidem is 5 ng/mL; LOQ is 10 ng/mL.
ULU4Z7	Internal Standard - Mepivacaine
V6X936	Since our state has not established per levels we do not report the uncertainty associated but we have established it and will report if requested. In that case it would be reported zolpidem 272.47 (+/- 49.04) ng/ml. The uncertainty is calculated at a coverage factor of K3.
VLAMK3	Screening and quantitation: UPLC-QTOF MS (Waters). - Salting-out assisted extraction. - Internal Standards: Cyclobarbitone, Prazepam & D3-Methadone - LOD for Zolpiderm: 5 ng/mL
VWMPYA	Codiene D3 was used as internal standard
VX37ZU	Zolpidem LOQ: 5ng/mL; ISTD: Zolpidem-D6 *Result for Zolpidem on the second extraction was greater than the linear range of 250.00ng/mL.
WK9AC2	internal standard: mepivacaine, mephobarital = LC-HRMS/MS, mepivacaine = LC/MS/MS, limit of report: for zolpidem = 0.025mg/L
X2PRKR	GC-MS and GC-FID were performed. Zolpidem is qualitative only on the FID, and it was positive. Internal standard used was Mepivacaine. LC/MS/MS was performed to confirm and quantitate the Zolpidem. Internal standard used was Diazepam-D5.
X69MMK	THE INTERNAL STANDARD USED WAS ESTAZOLAM.
XA9XJK	Internal standard: flurazepam, LoD: 10 ng/mL. The lab does not perform analysis of THC in blood.
XKMVNN	Internal standard: Flurazepam.
XXRDW3	Mepivacaine used as internal standard for LC/MS/MS method. Limit of report for zolpidem in quant method is 0.025 mg/L.
Y97MZL	Promazine - Internal Standard for Butyl Acetate Screen
YFQNFY	No additional testing performed.
YKLHDZ	internal standard: SKF-525A
YLWK2K	Internal standard used for GC/MS drug screen was Promazine.

TABLE 2F: Item 2

Webcode	Item 2 - Comments
Z6ZP3Y	SKF-525A used as the ISTD for Zolpidem.
Z8QNGW	Mepivacaine used as internal standard
ZMZJU6	Only Screening Testing performed.
ZUPRKP	Our lab does not currently have a confirmatory method for zolpidem.

Screening Results - Item 3

TABLE 3A: Item 3

Item Scenario:

A 45 year-old male was involved in a bar fight. He was taken to the hospital for injuries where it was noted that his blood pressure was elevated and his pupils were dilated. He was also exhibiting aggressive behavior. Blood samples were collected at the hospital.

Item Contents and Preparation Concentration: Cocaine (800 ng/mL)
Benzoylecgonine (640 ng/mL)

Webcode	Screening Results
2ACRQF	Cocaine Benzoylecgonine
2E8LNG	Cocaine
2EPH94	benzoylecgonine
2UG8AR	Cocaine/Cocaine Metabolite
2XJ9AP	Cocaine
3KCMK6	Cocaine and/or metabolites.
3KPCLW	Cocaine/BE
44YQHG	Cocaine
4BYD8V	Benzoylecgonine Cocaine Ecgonine Methyl Ester
4DPCNF	Cocaine Cocaine metabolite(s)
4XTWNL	Benzoylecgonine
629PCT	cocaine/metabolites
66889Z	Cocaine Benzoylecgonine
6LRX8Y	Cocaine Benzoylecgonine
727GLK	Cocaine and Metabolites
76GRCU	Benzoylecgonine Cocaine
7BRH4F	Cocaine
7NHE4T	Cocaine
7VEA3C	benzoylecgonine
86YZ3A	Cocaine and Metabolites
8ACPKX	Benzoylecgonine/cocaine
8EL42W	Benzoylecgonine
8EMV2P	cocaine benzoylecgonine acetaminophen
8R99DY	Cocaine
8VB7NR	cocaine metabolite (benzoylecgonine)

TABLE 3A: Item 3

Webcode	Screening Results
8Z9QTB	Cocaine, Benzoylecgonine
97CUGN	cocaine and benzoylecgonine
9RQG6E	Cocaine/Benzoylecgonine
9Z4P7G	Benzoylecgonine Cocaine
AD4T2U	Cocaine Benzoylecgonine Ecgonine methyl ester Anhydroecgonine methyl ester
APGREB	Cocaine and metabolite benzoilecgonine
B2QQLN	Cocaine/metabolites
B3FFJA	Cocaine, Benzoylecgonine
B6P3HN	Cocaine/Benzoylecgonine
BMATGN	cocaine/benzoylecgonine
CEATHL	benzoylecogonine cocaine
CF3P4U	cocaine and metabolites
CG2P7F	Cocaine
CGDN2N	cocaine metabolites
CLC3NE	Cocaine/BE
CVTQGR	Cocaine Benzoylecgonine
CWUJGK	Cocaine metabolites
D2FWTT	Cocaine and metabolites
DB6MH7	Cocaine
DCFLCE	No drugs/metabolites detected
DE4XBK	Cocaine Benzoyl Ecgonine Ecgonine Methyl Ester
DQLF7C	Benzoylecognine
DVT9XM	Benzoylecgonine/Cocaine breakdown product, Cocaine
E2DN47	Coacaine
E7TWPJ	Benzoylecgonine Cocaine
E9WUZC	Cocaine / Benzoylecgonine
EBNQP7	[Participant reported that drugs were detected, but did not report the drug class or name]
EJEBTJ	cocaine, benzoylecognine
EPJ8E6	Cocaine
EVQXHB	cocaine, benzoylecgonine
EZLREC	Cocaine
FGNPD2	Cocaine Metabolite

TABLE 3A: Item 3

Webcode	Screening Results
FLCGGN	Cocaine, Benzelecgonine
FZZBY9	Benzoylecgonine
G4R6AF	Benzoylecgonine Cocaine
GHBM66	Cocaine and metabolites.
GQTWT2	Cocaine Benzoylecgonine
HPRHKY	benzoylecgonine cocaine
HQNYVB	Benzoylecgonine, Cocaine.
HRVE42	Benzoylecgonine Cocaine Methylecgonine
HU693M	Cocaine Benzoylecgonine
HUNAQB	Benzoylecgonine
J8N9E8	Cocaine/Benzoylecgonine
JMF7F3	Cocaine and metabolites
K2UQD2	Cocaine
KB6TY2	Cocaine/Benzoylecgonine
KD9NH6	Benzoylecgonine (a cocaine metabolite)
KG9YE6	Cocaine drug class screened positive.
KMY9N3	cocaine
KPYPTJ	cocaine and benzoylecgonine
KQAJEC	cocaine metabolite
KQYHTD	Benzoylecgonine and cocaine
KRRDFL	Benzoylecognine/ Cocaine metabolite
KWZWFZ	Cocaine
L2AAXX	Cocaine and metabolites
LCTQQ6	Cocaine or its Metabolites
LG7QMW	Cocaine/BE
LX9D7H	Benzoylecgonine
MLCHP3	Benzoylecgonine
N8QPEZ	Benzoylecgonine Cocaine
NAX8DW	Benzoylecgonine
NLB4HZ	Cocaine
NW98LU	Cocaine Metabolite
NZRZXW	Benzoylecgonine Cocaine Methylecgonine

TABLE 3A: Item 3

Webcode	Screening Results
PLRKB8	cocaine, bze
PN98MR	Cocaine Metabolite
QE2PNU	Cocaine/Benzoylecgonine
QFHLGU	Cocaine and cocaine metabolites
QKPCJZ	Cocaine/Benzoylecgonine
QQGJ29	Cocaine, Benzoylecgonine, Naproxen, Caffeine, Anhydroecgonine methyl ester
QW7W4W	Cocaine/BE
R4ZNPV	Cocaine/cocaine metabolites
RJRLQQ	Cocaine/BE
RNLFNR	Cocaine
RTZY69	Benzoylecgonine detected. Cocaine detected. Acetaminophen detected, not confirmed. Carbinoxamine detected, could not be reported from run, was not detected by other methods.
RXACM8	Benzoylecgonine, Cocaine
T9PLQQ	No analysis carried out
TJN2UA	Cocaine, Benzoylecgonine
TR2B4N	Cocaine Benzoylecgonine
U89QNV	Cocaine
UAZMDP	Benzoylecgonine Cocaine Sertraline
UHR3Z9	Cocaine
ULU4Z7	Cocaine, Benzoylecgonine
V6X936	cocaine benzoylecgonine/cocaine breakdown product
VGTEXP	Benzoylecgonine
VLAMK3	Cocaine and metabolites
VWMPYA	Cocaine (Benzoyl Ecognine)
VX37ZU	Benzoylecgonine Cocaine
VXFV2L	Benzoylecgonine, Cocaine
WD9MML	Cocaine Benzoylecgonine
WK9AC2	cocaine and benzoylecgonine
WZN8JM	cocaine class
X2PRKR	Cocaine and/or cocaine metabolites presumptively positive
X69MMK	COCAINE BENZOYLECGONINE
XA9XJK	COCAINE AND ITS METABOLITES BENZOYL ECGONINE AND ECGONINE METHYL ESTER.

TABLE 3A: Item 3

Webcode	Screening Results
XKMVNN	No drugs/metabolites detected
XTGZE4	Cocaine, Benzoylecgonine
XXRDW3	Cocaine, benzoylecgonine
Y32RE2	Cocaine Metabolite
Y97MZL	Cocaine/Metabolite
YFQNFY	Cocaine
YKLHDZ	Cocaine Metabolite
YLWK2K	Cocaine/Benzoylecgonine
Z6ZP3Y	Cocaine metabolite
Z8QNGW	Cocaine and Benzoylecgonine
ZAJJ6Q	Cocaine and cocaine metabolites
ZJ6NDQ	Cocaine/Benzoylecgonine
ZJMUCG	Cocaine and Metabolites
ZMZJU6	Cocaine/metabolite
ZUPRKP	Benzoylecgonine

Item 3 - Response Summary	Participants Reporting Screening Results: 135
Cocaine and/or cocaine metabolites:	131
No drugs/metabolites detected:	2
*Other:	8

Participants can report multiple drugs/metabolites; therefore, the sum of the values here may be greater than the total number of participants responding for this item.

*This category represents the total number of participants that reported a response other than that which is listed above.

Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?

TABLE 3B: Item 3

Item Scenario:

A 45 year-old male was involved in a bar fight. He was taken to the hospital for injuries where it was noted that his blood pressure was elevated and his pupils were dilated. He was also exhibiting aggressive behavior. Blood samples were collected at the hospital.

Item Contents and Preparation Concentration: Cocaine (800 ng/mL)
Benzoylecgonine (640 ng/mL)

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2ACRQF	Cocaine		45.76	5.03	ng/mL
	Benzoylecgonine		693.23	76.25	ng/mL
2E8LNG	Cocaine	✓			
	Benzoylecgonine	✓			
2EPH94	Bezoylecgonine		1034.8		ng/mL
2UG8AR	Cocaine		34	7	ng/mL
	Benzoylecgonine		1,193	239	ng/mL
2XJ9AP	Cocaine	✓			
	Anhydroecgonine Methyl Ester	✓			
3DN4Z2	No drugs/metabolites detected				
3KCMK6	Cocaine	✓			ug/mL
44YQHG	Cocaine	✓			
4BYD8V	Cocaine	✓			
	Benzoylecgonine	✓			
4DPCNF	Cocaine		160	30	%
	Benzoylecgonine		1040	26	%
629PCT	cocaine		34	10	µg/L
	benzoylecgonine		1.1	0.3	mg/L
66889Z	cocaine		0.076	0.0092	mg/L
	benzoylecgonine		1.2	0.15	mg/L
6LRX8Y	Cocaine		88	10	ng/mL
	Benzoylecgonine		958	112	ng/mL
76GRCU	Cocaine	✓			
	Benzoylecgonine	✓			
7BRH4F	Cocaine	✓			
	Benzoylecgonine	✓			
7NHE4T	Cocaine		25	±3	ng/mL
	Benzoylecgonine		>1000		ng/mL

TABLE 3B: Item 3

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
7VEA3C	cocaine	✓			
	benzoylecgonine	✓			
86YZ3A	Cocaine		0.05	14%	ug/mL
	Benzoylecgonine		0.96	14%	ug/mL
8ACPKX	Cocaine		74		ng/mL
	Benzoylecgonine		1200		ng/mL
	Methylecgonine	✓			
8EL42W	Benzoylecgonine	✓			
8EMV2P	cocaine		22	6	µg/L
	benzoylecgonine		1.1	0.3	mg/L
8R99DY	Cocaine	✓			
8VB7NR	cocaine	✓			
	benzoylecgonine	✓			
8Z9QTB	Cocaine		64.65	16%	ug/L
	Benzoylecgonine		1226.61	7.7%	ug/L
97CUGN	cocaine		59	17	mcg/L
	benzoylecgonine		1.1	0.3	mg/L
9RQG6E	Cocaine	✓			
	ECME	✓			
9Z4P7G	Cocaine	✓			
	Benzoylecgonine	✓			
AD4T2U	Cocaine	✓			
	Benzoylecgonine	✓			
	Anhydroecgonine methyl ester	✓			
	Ecgonine methyl ester	✓			
APGREB	cocaine	✓			
	benzoilecgonine	✓			
B2QQLN	Cocaine		29	4	ng/mL
	Benzoylecgonine		>1000	139	ng/mL
B3FFJA	Cocaine	✓			
	Benzoylecgonine	✓			
B6P3HN	Cocaine		29	+/- 4	ng/mL
	Benzoylecgonine		> 1000		ng/mL
BMATGN	cocaine		0.11	0.01	mg/L
	benzoylecgonine		> 0.4	NA	mg/L

TABLE 3B: Item 3

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
CEATHL	cocaine		32	9	mcg/L
	benzoylecgonine		1.2	0.3	mg/L
CF3P4U	cocaine		56	9	ng/mL
	benzoylecgonine (BZE)		1.1	0.2	ug/mL
CG2P7F	cocaine	✓			
CGDN2N	cocaine		53		ng/mL
	benzoylecgonine		1099		ng/mL
	ecgonine methyl ester		17		ng/mL
CLC3NE	Cocaine	✓			
CVTQGR	Cocaine		67.4	12.8	ng/mL
	Benzoylecgonine		983.0	235.9	ng/mL
CWUJGK	Cocaine		53	4	ng/mL
	Benzoylecgonine		1301	104	ng/mL
D2FWTT	cocaine		57	±9	ng/ml
	benzoylecgonine		1.0	±0.2	µg/ml
DB6MH7	Cocaine		79.29	4.9	%
	Benzoylecgonine		1092.39	3.2	%
DCFLCE	Cocaine		0.055	0.007	mg/L
	Benzoylecgonine		1.1	0.2	mg/L
DE4XBK	Cocaine		0.02	0.002	mg/L
	Benzoyl Ecgonine		1.1	0.088	mg/L
	Ecgonine Methyl Ester		< 0.01		mg/L
DVT9XM	Cocaine	✓			
	Benzoylecgonine/Cocaine breakdown product	✓			
E2DN47	Cocaine	✓			
	Benzylecgonine	✓			
E7TWPJ	Benzoylecgonine		1100	300	ng/mL
E9WUZC	Cocaine	✓			
	Anhydroecgonine Methyl Ester	✓			
	Ecgonine Methyl Ester	✓			
EBNQP7	Cocaine	✓			
	Benzoylecgonine	✓			
EJEBTJ	cocaine		40	12	mcg/L
	benzoylecognine		1.1	0.3	mg/L

TABLE 3B: Item 3

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
EPJ8E6	Cocaine		67	8.6	%
	Benzoylecgonine		1196	13	%
EVQXHB	cocaine		116,00	30%	ng/ml
	benzoylecgonine		910,90	30%	ng/ml
EZLREC	Cocaine	✓			
	Anhydroecgonine Methyl Ester	✓			
	Ecgonine Methyl Ester	✓			
FGNPD2	Cocaine	✓			
	Benzoylecgonine	✓			
FLCGGN	Cocaine		77	9	ng/mL
	Benzoylecgonine		824	96	ng/mL
G4R6AF	Cocaine		55	18	ng/mL
	Benzoylecgonine		>1000		ng/mL
GHBM66	Cocaine		41,5		ng/mL
	Benzoylecgonine		540		ng/mL
	Anhydroecgonine methyl ester	✓			
	Ecgonine methyl ester	✓			
GQTWT2	Cocaine	✓			
	Benzoylecgonine	✓			
HPRHKY	cocaine		78		ng/mL
	benzoylecgonine		984		ng/mL
HQNYVB	Cocaine		0.042	0.005	mg/L
	Benzoylecgonine		1.2	0.2	mg/L
HRVE42	Cocaine	✓			
	Benzoylecgonine	✓			
	Methylecgonine	✓			
HU693M	cocaine		0.063	0.0076	mg/L
	benzoylecgonine		1.0	0.13	mg/L
HUNAQB	Cocaine	✓			
	Benzoylecgonine	✓			
J8N9E8	Cocaine	✓			
JMF7F3	Cocaine	✓			
	Benzoylecgonine	✓			
K2UQD2	Cocaine	✓			
	Benzoylecgonine	✓			
KB6TY2	Cocaine	✓			

TABLE 3B: Item 3

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
KG9YE6	Cocaine	✓			
KMY9N3	cocaine	✓			
	ecgonine methyl ester	✓			
KPYPTJ	cocaine	✓			
	benzoylecgonine	✓			
KQAJEC	cocaine		0.034	0.006	mcg/ml
	benzoylecgonine		1.10	0.16	mcg/ml
KQYHTD	Cocaine		45	13	ng/mL
	Benzoylecgonine		1.1	0.3	mg/L
KRRDFL	Cocaine	✓			
	Ecognine Methyl Ester	✓			
KWZWFZ	Cocaine		44	4	ng/mL
	Benzoylecgonine		>1000	n/a	ng/mL
L2AAXX	Cocaine	✓			
	Benzoylecgonine	✓			
LCTQQ6	Cocaine	✓			
	Anhydroecognine Methyl Ester	✓			
LG7QMW	Cocaine	✓			
	Benzoylecgonine	✓			
LX9D7H	Benzoylecgonine		1.12	+/-0.007	ug/ml
N8QPEZ	Cocaine		98.06	11.76	ng/ml
	Benzoylecgonine		1181.15	295.28	ng/ml
NAX8DW	Benzoylecgonine		1306.7	108	ng/mL
NLB4HZ	Cocaine	✓	Positive		
NW98LU	Cocaine		53	8	ng/mL
	Benzoylecgonine		1176	160	ng/mL
NZRZXW	Cocaine	✓			
	Benzoylecgonine	✓			
	Methylecgonine	✓			
PLRKB8	cocaine		64	19	mcg/L
	benzoylecgonine		1.1	0.3	mg/L
PN98MR	cocaine	✓			
	benzoylecgonine	✓			
QE2PNU	Cocaine	✓			
QFHLGU	Cocaine	✓			
	Benzoylecgonine	✓			

TABLE 3B: Item 3

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
QKPCJZ	Cocaine	✓			
	Anhydroecgonine Methyl Ester	✓			
	Ecgonine Methyl Ester	✓			
QQGJ29	Cocaine		0.0362	0.0037	mg/L
	Benzopylecgonine		1.06	0.11	mg/L
	Anhydroecgonine methyl ester	✓			
	Caffeine	✓			
	Naproxen	✓			
QW7W4W	Cocaine	✓			
	Ecgonine Methyl Ester	✓			
R4ZNPV	Cocaine	✓			
	Ecgonine Methyl Ester	✓			
RJRLQQ	Cocaine	✓			
	Benzoylecgonine	✓			
RNLFNR	Cocaine	✓			
	Benzoylecgonine	✓			
RTZY69	Cocaine	✓			
	Benzoylecgonine	✓			
RXACM8	Cocaine		93.62	18.73	ng/mL
	Benzoylecgonine		1200.53	240.11	ng/mL
TJN2UA	Cocaine		54	6.5	ng/mL
	Benzoylecgonine		1280	128	ng/mL
TR2B4N	Cocaine	✓			
	Benzoylecgonine	✓			
U89QNV	Cocaine	✓			
	Anhydroecgonine Methyl Ester	✓			
	Ecgonine Methyl Ester	✓			
UAZMDP	Cocaine		73.8 ng/mL		
	Benzoylecgonine		1122.6 ng/mL		
UHR3Z9	Cocaine		55	9	ng/mL
	Benzoylecgonine		1.1	0.2	µg/mL
ULU4Z7	Cocaine	✓			
	Benzoylecgonine	✓			
V6X936	cocaine	✓			
	benzoylecgonine/cocaine breakdown product	✓			
VGTEXP	Benzoylecgonine	✓			

TABLE 3B: Item 3

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
VLAMK3	Cocaine		20	2	ng/mL
	Benzoylecgonine		1000	100	ng/mL
	Methylecgonine		8	2	ng/mL
VWMPYA	Cocaine	✓			
	Benzoyl Ecognine	✓			
VX37ZU	Cocaine		70.98	8.51	ng/mL
	Benzoylecgonine		1439.66	359.91	ng/mL
VXFV2L	Cocaine	✓			
	Benzoylecgonine	✓			
WD9MML	Cocaine	✓			
	Benzoylecgonine	✓			
WK9AC2	cocaine		29	8	µg/L
	benzoylecgonine		1.1	0.3	mg/L
WMYBHP	Cocaine	✓			
	Benzoylecgonine	✓			
WZN8JM	cocaine		136	+/-7.4%	ug/L
	benzoylecgonine		962	+/-9.1%	ug/L
X2PRKR	Cocaine	✓	Positive		
	Anhydroecgonine Methyl Ester	✓	Positive		
	Ecgonine Methyl Ester	✓	Positive		
X69MMK	COCAINE	✓			
	BENZOYLECGONINE	✓			
XA9XJK	COCAINE	✓			
	BENZOYLECGONINE	✓			
	ECGONINE METHYL ESTER	✓			
XKMVNN	Cocaine	✓			
	Benzoylecgonine	✓			
XTGZE4	Benzoylecgonine	✓			
XXRDW3	Cocaine		45	13	µg/L
	Benzoylecgonine		1.1	0.3	mg/L
Y32RE2	Cocaine	✓			
	Benzoylecgonine	✓			
Y97MZL	Cocaine	✓			
	Benzoylecgonine	✓			

TABLE 3B: Item 3

Webcode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
YFQNFY	Cocaine	✓			
	Benzoylecgonine	✓			
	ecgonine Methyl Ester	✓			
YKLHDZ	cocaine	✓			
	benzoylecgonine	✓			
YLWK2K	Cocaine	✓			
	Benzoylecgonine	✓			
Z6ZP3Y	Cocaine	✓			
	Benzoylecgonine	✓			
Z8QNGW	Cocaine		44	13	µg/L
	Benzoylecgonine		1.1	0.3	mg/L
ZAJJ6Q	Cocaine	✓			
	Anhydroecgonine Methyl Ester	✓			
	Ecgonine Methyl Ester	✓			
ZJ6NDQ	Cocaine	✓			
ZJMUCG	Cocaine		85		ng/mL
	Benzoilecgonine		940		ng/mL
	Ecgonine methyl ester	✓			

Item 3 - Response Summary **Participants Reporting Confirmatory Results: 127**

Cocaine:	119
Benzoylecgonine:	102
No drugs/metabolites detected:	1
*Other:	34

Participants can report multiple drugs/metabolites therefore the sum of the values here may be greater than the total number of participants responding for this item.

*This category represents the total number of participants that reported a response other than that which is listed above, including additional metabolites of cocaine.

Raw Data - Item 3

List of raw data determinations in ng/mL.

TABLE 3C: Item 3

Item 3 Raw Data - Cocaine
Preparation concentration: 800 ng/mL

Webcode	Raw Data (ng/mL)		Participant Mean
2ACRQF	45.76		45.76
2UG8AR	34.00		34.00
4DPCNF	[No raw data reported]		
629PCT	33.62		33.62
66889Z	76.76		76.76
6LRX8Y	88.00		88.00
7NHE4T	25.30		25.30
86YZ3A	53.00		53.00
8ACPKX	74.21		74.21
8EMV2P	22.44		22.44
8Z9QTB	64.65	56.78	60.72
97CUGN	59.01		59.01
B2QQLN	29.10		29.10
B6P3HN	29.10		29.10
BMATGN	104.4	107.4	105.9
CEATHL	31.93		31.93
CF3P4U	56.96		56.96
CGDN2N	53.00		53.00
CVTQGR	67.40		67.40
CWUJGK	53.90	52.55	53.23
D2FWTT	57.75		57.75
DB6MH7	79.29	83.55	81.42
DCFLCE	54.80	55.00	54.90
DE4XBK	19.00	18.00	18.50
EJEBTJ	39.57		39.57
EPJ8E6	67.00		67.00
EVQXHB	116.0		116.0
FLCGGN	77.00		77.00

TABLE 3C: Item 3

Item 3 Raw Data - Cocaine
Preparation concentration: 800 ng/mL

Webcode	Raw Data (ng/mL)				Participant Mean
G4R6AF	55.29				55.29
GHBM66	40.00	43.00			41.50
HPRHKY	78.00				78.00
HQNYVB	41.00	42.40	41.80	43.30	42.13
HU693M	63.16				63.16
KQAJEC	34.00				34.00
KQYHTD	44.54				44.54
KWZWFZ	[No raw data reported]				
N8QPEZ	98.06				98.06
NW98LU	53.00				53.00
PLRKB8	63.74				63.74
QQGJ29	40.36	32.10			36.23
RXACM8	[No raw data reported]				
TJN2UA	[No raw data reported]				
UAZMDP	[No raw data reported]				
UHR3Z9	55.19				55.19
VLAMK3	22.00	23.00			22.50
VX37ZU	70.98	71.60			71.29
WK9AC2	29.12				29.12
WZN8JM	[No raw data reported]				
XXRDW3	45.04				45.04
Z8QNGW	43.80				43.80
ZJMUCG	[No raw data reported]				

Statistical Analysis for Item 3 - Cocaine

Grand Mean: **54.28**
Number of Participants Included: **44**
Number of Participants without Raw Data or Data that was not reported in ng/mL: **7**
Standard Deviation: **22.69**
Number of Participants Excluded: **0**

TABLE 3C: Item 3

Item 3 Raw Data - Benzoylecgonine
Preparation concentration: 640 ng/mL

Webcode	Raw Data (ng/mL)			Participant Mean	
2ACRQF	693.2			693.2	X
2EPH94	1,034.8			1,034.8	
2UG8AR	1,193.0			1,193.0	
4DPCNF	[No raw data reported]				
629PCT	1,085.8			1,085.8	
66889Z	1,272.2			1,272.2	
6LRX8Y	958.0			958.0	
7NHE4T	1,006.6			1,006.6	
86YZ3A	956.0			956.0	
8ACPKX	1,162.9			1,162.9	
8EMV2P	1,025.2	1,125.5	1,093.6	1,081.4	
8Z9QTB	1,226.6	1,138.6		1,182.6	
97CUGN	1,129.5			1,129.5	
B2QQLN	1,018.4			1,018.4	
B6P3HN	1,033.2			1,033.2	
BMATGN	[No raw data reported]				
CEATHL	1,199.3	1,211.4	1,101.0	1,170.6	
CF3P4U	1,105.8			1,105.8	
CGDN2N	1,099.0			1,099.0	
CVTQGR	983.0			983.0	
CWUJGK	1,304.3	1,297.5		1,300.9	
D2FWTT	1,099.9			1,099.9	
DB6MH7	1,092.4	1,121.1		1,106.8	
DCFLCE	1,135.0	1,135.0		1,135.0	
DE4XBK	1,052.0	1,067.0		1,059.5	
E7TWPJ	1,140.0	1,040.0	1,150.0	1,110.0	
EJEBTJ	1,084.0			1,084.0	
EPJ8E6	1,196.0			1,196.0	
EVQXHB	910.9			910.9	
FLCGGN	824.0			824.0	
G4R6AF	1,046.0			1,046.0	

TABLE 3C: Item 3

Item 3 Raw Data - Benzoylecgonine
Preparation concentration: 640 ng/mL

Webcode	Raw Data (ng/mL)						Participant Mean	
GHBM66	540.0						540.0	X
HPRHKY	984.0						984.0	
HQNYVB	1,220.0	1,220.0	1,180.0	1,210.0			1,207.5	
HU693M	1,033.4						1,033.4	
KQAJEC	1,101.0						1,101.0	
KQYHTD	1,111.0						1,111.0	
KWZWFZ	[No raw data reported]							
LX9D7H	1,118.8	1,113.7					1,116.3	
N8QPEZ	1,181.2						1,181.2	
NAX8DW	1,374.1	1,366.5	1,366.5	1,180.9	1,122.8	1,336.5	1,291.2	
NW98LU	1,176.0						1,176.0	
PLRKB8	1,064.9						1,064.9	
QQGJ29	1,045.8	1,072.7					1,059.2	
RXACM8	[No raw data reported]							
TJN2UA	[No raw data reported]							
UAZMDP	[No raw data reported]							
UHR3Z9	1,149.6						1,149.6	
VLAMK3	1,051.0	1,039.0					1,045.0	
VX37ZU	1,439.7						1,439.7	X
WK9AC2	1,120.9	1,125.2					1,123.1	
WZN8JM	[No raw data reported]							
XXRDW3	1,071.0						1,071.0	
Z8QNGW	1,131.0						1,131.0	
ZJMUCG	[No raw data reported]							

Statistical Analysis for Item 3 - Benzoylecgonine

Grand Mean: 1,095.3

Number of Participants Included: 44

Number of Participants without Raw Data or Data that was not reported in ng/mL: 8

Standard Deviation: 95.28

Number of Participants Excluded: 3

TABLE 3C: Item 3

Item 3 Raw Data - Other

Webcode	Analyte	Raw Data (ng/mL)	
CGDN2N	ecgonine methyl ester	17.00	
DE4XBK	Ecgonine Methyl Ester	8.000	9.000
VLAMK3	Methylecgonine	7.000	8.000

Statistical Analysis for Item 3 - Other

Please note statistical analysis has not been provided due to the low number of raw data responses.

Reporting Procedures - Item 3

If quantitative analysis was performed, the reported concentrations are:

TABLE 3D: Item 3

WebCode	Quantitative Reporting Procedures
2ACRQF	A single determination.
2EPH94	A single determination.
2UG8AR	A single determination.
2XJ9AP	A single determination.
3KCMK6	A single determination.
4DPCNF	The mean of duplicate/several determinations.
629PCT	A single determination.
66889Z	A single determination.
6LRX8Y	A single determination.
7NHE4T	A single determination.
86YZ3A	A single determination.
8ACPKX	A single determination.
8EMV2P	The mean of duplicate/several determinations.
8Z9QTB	A single determination.
97CUGN	A single determination.
APGREB	qualitative
B2QQLN	A single determination.
B6P3HN	A single determination.
BMATGN	The mean of duplicate/several determinations.
CEATHL	cocaine: single determination; benzoylecgonine: mean of duplicate/several determinations
CF3P4U	A single determination.
CG2P7F	A single determination.
CGDN2N	A single determination.
CVTQGR	A single determination.
CWUJGK	The mean of duplicate/several determinations.
D2FWTT	A single determination.
DB6MH7	A single determination.

TABLE 3D: Item 3

WebCode	Quantitative Reporting Procedures
DCFLCE	The mean of duplicate/several determinations.
E7TWPJ	The mean of duplicate/several determinations.
EJEBTJ	A single determination.
EPJ8E6	A single determination.
EVQXHB	A single determination.
EZLREC	A single determination.
FLCGGN	A single determination.
G4R6AF	A single determination.
GHBM66	Single or duplicate determinations.
HPRHKY	A single determination.
HQNYVB	The mean of duplicate/several determinations.
HU693M	A single determination.
KQAJEC	A single determination.
KQYHTD	A single determination.
KWZWFZ	A single determination.
LCTQQ6	A single determination.
LX9D7H	The mean of duplicate/several determinations.
N8QPEZ	A single determination.
NAX8DW	The mean of duplicate/several determinations.
NLB4HZ	A single determination.
NW98LU	A single determination.
PLRKB8	A single determination.
QQGJ29	The mean of duplicate/several determinations.
R4ZNPV	No quant performed
RXACM8	A single determination.
TJN2UA	A single determination.
U89QNV	A single determination.
UAZMDP	A single determination.
UHR3Z9	A single determination.
VLAMK3	The mean of duplicate/several determinations.

TABLE 3D: Item 3

WebCode	Quantitative Reporting Procedures
VX37ZU	Sample was screened and confirmed on a quantitative method, the lower of the two values is the reported concentration
WK9AC2	single determination for cocaine, mean of duplicate for benzoylecgonine
WZN8JM	single determination confirmed with dilution
X2PRKR	A single determination.
XXRDW3	A single determination.
Z8QNGW	A single determination.
ZAJJ6Q	A single determination.
ZJMUCG	A single determination.

Response Summary for Item 3		Participants: 65
A single determination:	47 (72.3%)	
The mean of duplicate/several determinations:	11 (16.9%)	
Other:	7 (10.8%)	

Methods of Analysis - Item 3

TABLE 3E: Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
2ACRQF	LC/MS/MS	✓	✓	✓
2E8LNG	Immunoassay	✓		
	GC/MS		✓	
2EPH94	Immunoassay	✓		
	LC/MS/MS		✓	✓
2UG8AR	Immunoassay	✓		
	GC/MS		✓	✓
2XJ9AP	Immunoassay	✓		
	GC/MS		✓	
3DN4Z2	GC/MS		✓	
3KCMK6	GC/MS		✓	
3KPCLW	Immunoassay	✓		
44YQHG	Immunoassay	✓		
	GC/MS		✓	
4BYD8V	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	
4DPCNF	Immunoassay	✓		
	GC/MS	✓	✓	✓
4XTWNL	Immunoassay	✓		
629PCT	Immunoassay	✓		
	GC/MS		✓	✓
66889Z	LC-TOF-MS	✓		
	GC/MS		✓	✓
6LRX8Y	LC/MS/MS	✓	✓	✓
727GLK	Immunoassay	✓		
76GRCU	LC/MS/MS	✓	✓	
7BRH4F	Immunoassay	✓		
	GC/MS		✓	
7NHE4T	Immunoassay	✓		
	GC/MS		✓	✓
7VEA3C	Immunoassay	✓		
	GC/MS		✓	
86YZ3A	Immunoassay	✓		
	GC/MS		✓	✓
8ACPKX	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
8EL42W	Immunoassay	✓		
8EMV2P	LC-HRAMS	✓		
	GC/MS		✓	✓

TABLE 3E: Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
8R99DY	Immunoassay	✓		
	GC/MS		✓	
8VB7NR	Immunoassay	✓		
	GC/MS		✓	
8Z9QTB	Immunoassay	✓		
	GC/MS		✓	✓
97CUGN	LC-HRMS/MS	✓		
	GC/MS		✓	✓
9RQG6E	Immunoassay	✓		
	GC/MS		✓	
9Z4P7G	LC/MS/MS	✓	✓	
AD4T2U	LC/QTOF	✓		
	GC/MS		✓	
APGREB	LC/MS/MS	✓		
	GC/MS		✓	
B2QQLN	Immunoassay	✓		
	GC/MS		✓	✓
B3FFJA	Immunoassay	✓		
	GC/MS	✓	✓	
B6P3HN	Immunoassay	✓		
	GC/MS		✓	✓
BMATGN	LC/MS/MS		✓	✓
	Immunoassay	✓		
	QTOF	✓		
	GC/MS	✓		
CEATHL	LC-HRMS/MS	✓		
	GC/MS		✓	✓
CF3P4U	Immunoassay	✓		
	LC/MS/MS		✓	✓
CG2P7F	Immunoassay	✓		
	GC/MS		✓	
CGDN2N	Immunoassay	✓		
	LC/MS/MS		✓	✓
CLC3NE	Immunoassay	✓		
	GC/MS		✓	
CVTQGR	LC/MS/MS	✓	✓	✓
CWUJGK	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS			✓
D2FWTT	Immunoassay	✓		
	LC/MS/MS		✓	✓
DB6MH7	Immunoassay	✓		
	GC/MS		✓	✓

TABLE 3E: Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
DCFLCE	Immunoassay	✓		
	LC/MS		✓	
	LC/MS/MS			✓
DE4XBK	Immunoassay	✓		
	LC/MS/MS		✓	✓
	LC-QTOF/MS	✓		
DQLF7C	Immunoassay	✓		
DVT9XM	LC/MS/MS	✓	✓	
E2DN47	Immunoassay	✓		
	LC/MS/MS		✓	
E7TWPJ	Immunoassay	✓		
	LC-TOFMS	✓		
	LC/MS/MS		✓	✓
E9WUZC	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID	✓	✓	
EBNQP7	LC/MS/MS		✓	
EJEBTJ	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS	✓		
EPJ8E6	Immunoassay	✓		
	GC/MS	✓	✓	✓
EVQXHB	LC/MS/MS	✓	✓	✓
	GC/MS	✓	✓	
EZLREC	Immunoassay	✓		
	GC/MS		✓	
	GC/FID			✓
FGNPD2	Immunoassay	✓		
	GC/MS		✓	
FLCGGN	LC/MS/MS	✓	✓	✓
FZZBY9	Immunoassay	✓		
G4R6AF	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS	✓	✓	✓
GHBM66	LC/MS/MS	✓		
	LC-HRMS	✓	✓	
	LC/MS			✓
GQTWT2	GC/MS		✓	
HPRHKY	LC/MS/MS	✓	✓	
HQNYVB	Immunoassay	✓		
	LC-QTOF	✓		
	LC/MS/MS		✓	✓
HRVE42	Immunoassay	✓		
	GC/MS		✓	
	LC/QTOF-MS	✓		

TABLE 3E: Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
HU693M	LC-TOF-MS	✓		
	GC/MS		✓	✓
HUNAQB	Immunoassay	✓		
	GC/MS		✓	
J8N9E8	Immunoassay	✓		
	GC/MS		✓	
JMF7F3	Immunoassay	✓		
	GC/MS	✓	✓	
K2UQD2	Immunoassay	✓		
	GC/MS		✓	
KB6TY2	Immunoassay	✓		
	GC/MS		✓	
KD9NH6	Immunoassay	✓		
KG9YE6	Immunoassay	✓		
	GC/MS	✓	✓	
KMY9N3	Immunoassay	✓		
	GC/MS		✓	
KPYPTJ	LC/MS/MS	✓	✓	
KQAJEC	Immunoassay	✓		
	GC/MS		✓	✓
KQYHTD	LC-HRMS/MS	✓		
	GC/MS		✓	✓
KRRDFL	Immunoassay	✓		
	GC/MS		✓	
KWZWFZ	Immunoassay	✓		
	GC/MS		✓	✓
L2AAXX	Immunoassay	✓		
	GC/MS	✓	✓	
LCTQQ6	Immunoassay	✓		
	GC/MS		✓	✓
LG7QMW	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
LX9D7H	Immunoassay	✓		
	LC/MS - QTOF		✓	✓
MLCHP3	Immunoassay	✓		
N8QPEZ	LC/MS/MS	✓	✓	✓
NAX8DW	LC/MS	✓		✓
	LC/MS/MS		✓	
NLB4HZ	Immunoassay	✓		
	GC/MS		✓	
NW98LU	Immunoassay	✓		
	GC/MS		✓	✓

TABLE 3E: Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
NZRZXW	Immunoassay	✓		
	LC/QTOF-MS	✓		
	GC/MS		✓	
PLRKB8	LC-HRMS/MS	✓		
	GC/MS		✓	✓
PN98MR	Immunoassay	✓		
	GC/MS		✓	
QE2PNU	Immunoassay	✓		
	GC/MS		✓	
QFHLGU	Immunoassay	✓		
	GC/MS	✓	✓	
QKPCJZ	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID	✓	✓	
QQGJ29	Immunoassay	✓		
	LC/MS/MS		✓	✓
	LC QTOF	✓	✓	
QW7W4W	Immunoassay	✓		
	GC/MS		✓	
	GC-FID		✓	
R4ZNPV	Immunoassay	✓		
	GC/MS		✓	
RJRLQQ	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
RNLFNR	Immunoassay	✓		
	GC/MS		✓	
RTZY69	Immunoassay	✓		
	QTOF	✓		
	GC/MS		✓	
RXACM8	LC/MS/MS	✓	✓	✓
TJN2UA	GC/MS	✓		
	LC/MS/MS	✓	✓	✓
TR2B4N	GC/MS		✓	
U89QNV	Immunoassay	✓		
	GC/MS-FID		✓	
UAZMDP	LC/MS/MS	✓	✓	✓
UHR3Z9	Immunoassay	✓		
	LC/MS/MS		✓	✓
ULU4Z7	Immunoassay	✓		
	LC-QTOFMS	✓		
	GC/MS		✓	
V6X936	LC/MS/MS	✓	✓	
VGTEXP	GC/MS	✓		
	LC/MS/MS	✓	✓	

TABLE 3E: Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
VLAMK3	Immunoassay	✓		
	LC/MS/MS			✓
	UPLC-QTOF MS	✓	✓	
VWMPYA	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
VX37ZU	LC/MS/MS	✓	✓	✓
VXFV2L	LC/MS/MS	✓	✓	
WD9MML	Immunoassay	✓		
	GC/MS		✓	
WK9AC2	LC-HRMS/LC	✓		
	GC/MS		✓	✓
WMYBHP	GC/MS		✓	
WZN8JM	Immunoassay	✓		
	GC/MS	✓	✓	✓
X2PRKR	Immunoassay	✓		
	GC/MS		✓	
	GC/FID		✓	
X69MMK	LC/MS	✓		
	LC/MS/MS		✓	
XA9XJK	GC/MS	✓		
	LC/MS/MS		✓	
XKMVNN	GC/MS		✓	
XTGZE4	Immunoassay	✓		
	LC/MS/MS		✓	
XXRDW3	Immunoassay	✓		
	GC/MS		✓	✓
Y32RE2	Immunoassay	✓		
	GC/MS		✓	
	LC-MS-QTOF	✓		
Y97MZL	Immunoassay	✓		
	GC/MS	✓	✓	
YFQNFY	Immunoassay	✓		
	LC/MS/MS	✓	✓	
YKLHDZ	Immunoassay	✓		
	GC/MS		✓	
YLWK2K	Immunoassay	✓		
	GC/MS	✓	✓	
Z6ZP3Y	Immunoassay	✓		
	GC/MS		✓	
Z8QNGW	LC-HR-MS/MS	✓	✓	
	LC/MS/MS		✓	✓
ZAJJ6Q	Immunoassay	✓		
	GC/MS		✓	

TABLE 3E: Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
ZJ6NDQ	Immunoassay	✓		
	GC/MS		✓	
ZJMUCG	Immunoassay	✓		
	GC/MS		✓	✓
ZMZJU6	Immunoassay	✓		
ZUPRKP	Immunoassay	✓		

Response Summary for Item 3 **Participants: 136**

	Screening	Confirmatory	Quantitation
Immunoassay:	96	0	0
GC/MS:	19	85	26
LC/MS:	3	1	2
LC/MS/MS:	22	41	26
Other:	25	10	2

Additional Comments for Item 3

TABLE 3F: Item 3

WebCode	Item 3 - Comments
2UG8AR	Internal Standard: Benzoylecgonine-d8 and Cocaine-d3. LOD/LOQ: 25.0 ng/mL for both analytes
3KCMK6	Cocaine is a qualitative only analysis.
3KPCLW	ELISA was used to screen the sample. The sample was screened using Immunalysis kits for Opiates, Benzodiazepines, PCP, Cocaine/BE, Cannabinoids and Methamphetamine.
44YQHG	Phenyltoloxamine (IRM) - Base fraction. Heptabarbital (IRM) - Acid fraction
4BYD8V	Acetaminophen indicated- not reported. Ecgonine methyl ester indicated- not reported. Cocaethylene indicated- not reported. Benzoylecgonine isopropyl ester indicated- not reported. GCMS and LC-QTOF-MS internal standard: Mepivacaine
4DPCNF	[From Table 3- Raw Data: Listing of raw data not used in statistical calculations "Item 3: Cocaine- 169.5, 158.2. Benzoylecgonine- 1029.7, 1059.8.]
4XTWNL	Assay- Cutoff* (ng/mL): Meth /Amphetamines- 20, Barbiturates -50, Benzodiazepines -10, Buprenorphine -5, Cannabinoids -10, Benzoylecgonine -50, Dextromethorphan -5, Fentanyl -1, Meprobamate -100, Methadone -10, Opiates -10, Opioids -10, Phencyclidine -5, TCA -25, Tramadol -5, Zolpidem -10.
629PCT	internal standard: mepivacaine, bze-d8
727GLK	Cocaine and Metabolites assay cutoff: 20 ng/mL
76GRCU	Benzoylecgonine limit of detection: 10 ng/mL. Cocaine limit of detection: 5 ng/mL. Benzoylecgonine is reported out as Benzoylecgonine/Cocaine breakdown product.
7BRH4F	Promazine - ISTD for Drug Screen
7NHE4T	The ELISA immunoassay was used to screen for six classes of drugs: amphetamines, benzodiazepines, cannabinoids, cocaine, opiates and PCP. The cocaine analysis was performed on the GC/MS. The cut off is 25 ng/mL. The internal standard used for cocaine and benzoylecgonine was cocaine-d3 and benzoylecgonine-d8, respectively. The compounds were extracted by solid phase extraction targeting free, non-conjugated/non-protein bound compounds. The concentration of benzoylecgonine exceeds the analytical linear range established by the laboratory for biological matrices. Therefore, the concentration is greater than the highest calibrator (1000 ng/mL).
86YZ3A	Benzoylecgonine: Internal standard = D3-Benzoylecgonine, LOD = 0.020 ug/mL. Cocaine: Internal standard = D3-Cocaine LOD = 0.020 ug/mL
8EL42W	Only Screening analysis was able to be performed by the laboratory.
8EMV2P	Negative acetaminophen
8Z9QTB	The internal standards used in quantitation were d3-Cocaine and d3-Benzoylecgonine. The quantitative range used in this analysis was 50-1000 ug/L.
97CUGN	The internal standard used to quantitate cocaine is mepivacaine. The internal standard used to quantitate benzoylecgonine is benzoylecgonine - d8.
9RQG6E	BE SIM is not completed if Cocaine is confirmed per policy.
APGREB	In this case, an detection limit of 30 ng / mL by Gas Chromatography with Mass Detector (GC / MS) was used for cocaine and metabolites. It was used as a screening method LC/ MS/MS where cocaine, benzoylecgonine, and methylecgonine are detected. Methylecgonine does not pass the detection limit established in blood of 30 ng / mL by GC / MS, therefore it is not reported.

TABLE 3F: Item 3

WebCode	Item 3 - Comments
B2QQLN	1) This specimen screened negative for the following assays: benzodiazepines, cannabinoids, amphetamines, opiates, and phencyclidine. 2) The specimen was 'none detected' for cocaethylene. 3) The cutoff for cocaine and benzoylecgonine is 25ng/mL. 4) The internal standard used for cocaine is cocaine-d3. 5) The internal standard used for benzoylecgonine is benzoylecgonine-d8. 6) The concentration of benzoylecgonine exceeds the analytical linear range established by the laboratory for biological matrices. Therefore, the concentration is greater than the highest calibrator.
B6P3HN	ELISA was used to screen the sample. The sample was screened using Immunalysis kits for Opiates, Benzodiazepines, PCP, Cocaine/BE, Cannabinoids and Methamphetamine. Cocaine-D3 and Benzoylecgonine-D8 was used as internal standards for Cocaine and Benzoylecgonine respectively, with a limit of detection of 25 ng/mL. The concentration of Benzoylecgonine exceeds the analytical linear range established by the laboratory for biological matrices. Therefore, the concentration is reported as greater than the highest calibrator.
CEATHL	Internal standard for cocaine is mepivacaine & for benzoylecgonine is benzoylecgonine-d8
CF3P4U	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Confirmation/quantitation of cocaine using cocaine D-3 as internal standard. LOQ/LOD for cocaine is 1 ng/mL. Confirmation/quantitation of benzoylecgonine using benzoylecgonine D-3 as internal standard. LOQ/LOD for benzoylecgonine is 10 ng/mL.
CLC3NE	For question 3-3) [Table 3D- Reporting Procedures], no circles should be filled in. I cannot totally clear out the fields once one has been chosen. I can only hop from circle to circle.
D2FWTT	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Cocaine confirmation panel includes cocaine and benzoylecgonine. Cocaine has a LOD/LOQ of 1ng/ml. Benzoylecgonine has a LOD/LOQ of 10ng/ml. Cocaine-D3 and benzoylecgonine-D3 were used as internal standards.
DCFLCE	The LC/MS used for confirmatory test was an LC/QTOF.
DQLF7C	Our lab currently doesn't have a method to confirm/quantitation benzoylecgonine.
DVT9XM	Calibration curve for benzoylecgonine/cocaine breakdown product limited to 5-100ng/mL in the confirmation testing. Cocaine calibration curve is 5-1000ng/mL. Both benzoylecgonine and cocaine are reported qualitatively only as per the SOP. LOD for benzoylecgonine/cocaine breakdown product is 10ng/mL. LOD for cocaine is 5ng/mL.
EZLREC	Mepivacaine IS
FGNPD2	Used D3-Cocaine and D3-Benzoylecgonine internal standards.
FLCGGN	Internal Standards: Cocaine-D3, Benzolecgonine-D3 Calibration Curves range from 10 - 1000 ng/mL
FZZBY9	Immunoassay cutoff concentrations (ng/mL): Meth /Amphetamines 20, Barbiturates 50, Benzodiazepines 10, Buprenorphine 5, Cannabinoids 10, Benzoylecgonine 50, Dextromethorphan 5, Fentanyl 1, Meprobamate 100, Methadone 10, Opiates 10, Opioids 10, Phencyclidine 5, TCA 25, Tramadol 5, Zolpidem 10.
G4R6AF	Benzoylecgonine ULOQ=1000 ng/mL
HQNYVB	LC-QTOF internal standards: Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, Triazolam-D4. LC/MS/MS internal standards: Benzoylecgonine-D3, Cocaine-D3.
HUNAQB	Cocaine D3 and Benzoylecgonine D3 as IS. Cocaine reporting limit is 10ng/mL. Benzoylecgonine reporting limit is 25ng/mL.

TABLE 3F: Item 3

WebCode	Item 3 - Comments
JMF7F3	Promazine utilized as ISTD for GC/MS screening test.
K2UQD2	Phenyltoloxamine and Hexobarbital were used as internal standards.
KD9NH6	Analysis by immunoassay screening in whole blood for: Analyte (Cutoff): Meth /Amphetamines (20), Barbiturates (50), Benzodiazepines (10), Buprenorphine (5), Cannabinoids (10), Benzoylecgonine (50), Dextromethorphan (5), Fentanyl (1), Meprobamate (100), Methadone (10), Opiates (10), Opioids (10), Phencyclidine (5), TCA (25), Tramadol (5), Zolpidem (10).
KQYHTD	Mepivacaine internal standard used for screening method. Mepivacaine and Benzoylecgonine-d8 internal standards used for confirmatory/quantitation method. LOD = 31 ng/mL for Benzoylecgonine and 8 ng/mL for cocaine.
KWZWFZ	Cocaine and Benzoylecgonine, lower reporting limit (LRL) is 10 ng/mL each. Cocaine and Benzoylecgonine, upper limit of linearity (ULOL) is 1000 ng/mL each.
L2AAXX	Drug Screen for Blood: Promazine ISTD used.
LG7QMW	Confirmatory ISTD for GC/MS: NPA and SKF Confirmatory ISTD for LC/MS/MS: Prazepam-d5
LX9D7H	Immunoassay by Randox analyzer
MLCHP3	Analyte- Cutoff: Meth /Amphetamines -20, Barbiturates -50, Benzodiazepines -10, Buprenorphine -5, Cannabinoids -10, Benzoylecgonine -50, Dextromethorphan -5, Fentanyl -1, Meprobamate -100, Methadone -10, Opiates -10, Opioids -10, Phencyclidine -5, TCA -25, Tramadol -5, Zolpidem -10.
N8QPEZ	Benzoylecgonine LOQ 5ng/ml; ISTD: Benzoylecgonine-D8 Cocaine LOQ 5ng/ml; ISTD: Cocaine-D3
PLRKB8	Internal standard used - mepivacaine and bze-d8
PN98MR	ISTDs = D3-Cocaine, D3-Benzoylecgonine
QE2PNU	Phenyltoloxamine IRM (base fraction), Heptabarbital IRM (acid fraction)
QFHLGU	Promazine was used as an internal standard for general drug screen test on GC/MS.
RJRLQQ	Confirmatory ISTD for GC/MS: NPA and SKF. Confirmatory ISTD for LC/MS/MS: Prazepam-d5
RNLFNR	Cocaine metabolite Methylecgonine also detected, not reportable due to drug exclusion on laboratory's drug panel.
RTZY69	Mepivacaine used as IS. Ecgonine Methyl Ester indicated in BSPE. Benzoylecgonine isopropyl ester indicated in BSPE.
UHR3Z9	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a positive cocaine screen, confirmation/quantitation of cocaine and benzoylecgonine performed using cocaine-D3 and benzoylecgonine-D3 as internal standards. LOQ/LOD for cocaine is 1 ng/mL; LOQ/LOD for benzoylecgonine is 10 ng/mL.
ULU4Z7	Internal Standard - Mepivacaine
VGTEXP	Traces (<10ng/ml) of cocaine and ecgonine methyl ester were also detected in the sample.
VLAMK3	Screening: Immunoassay and UPLC-QTOF MS (Waters). UPLC-QTOF MS: - Salting-out assisted extraction, - Internal Standards: Cyclobarbitone, Prazepam & D3-Methadone. Methylecgonine, Benzolecgonibe and Cocaine Quantitative Analysis: - Instrument: UPLC-TQD (Waters), - Internal Standard: D3-Benzoylecgonine and D3-Cocaine, - LOD for Methylecgonine, Benzolecgonibe and Cocaine: 2 ng/mL

TABLE 3F: Item 3

WebCode	Item 3 - Comments
VWMPYA	Codiene-D3 was used as internal standard
VX37ZU	Benzoylecgonine LOQ: 5ng/mL; ISTD: Benzoylecgonine-D8 Cocaine LOQ: 5ng/mL; ISTD: Cocaine-D3
WK9AC2	Internal Standard: mepivacaine,mephobarital = LC-HRMS/MS, mepivacaine = cocaine GC/MS, benzoylecgonine-d8 = benzoylecgonine GC/MS, limit of report: cocaine = 8 µg/L benzoylecgonine = 31 µg/L
WZN8JM	[From Table 3- Raw Data: Listing of raw data not used in statistical calculations "Item 3: Cocaine-135.98, Benzoylecgonine- 962.11.]
X2PRKR	Internal standard used was Mepivacaine; Qualitative only.
X69MMK	THE INTERNAL STANDARD USED WAS ESTAZOLAM.
XA9XJK	Internal standard: flurazepam, LoD: 10 ng/mL. The lab does not perform analysis of THC in blood.
XKMVNN	Cocaine LOD 50 ng/mL. Benzoylecgonine LOD 120 ng/mL. Internal standard: Flurazepam.
XTGZE4	Confirmation for cocaine was performed by GC/MS, but the results of 38.91ng/mL were below LOQ of 40ng/mL.
XXRDW3	Mepivacaine and benzoylecgonine-d8 are the internal standards used in the GC/MS method. The limit of report for cocaine is 8 µg/L and for benzoylecgonine is 31 µg/L.
Y97MZL	Promazine - Internal Standard for Butyl Acetate Screen
YKLHDZ	internal standards: D3-cocaine, D3-propylbenzoylecgonine. limit of detection for cocaine: 25 ng/mL.
YLWK2K	Internal standard used for GC/MS drug screen was Promazine.
Z6ZP3Y	D3-Cocaine was used as the ISTD for cocaine D3-propylbenzoylecgonine was used as the ISTD for benzoylecgonine
Z8QNGW	Mepivacaine internal standard for cocaine and benzoylecgonine-d8 is the internal standard for benzoylecgonine.
ZMZJU6	Only Screening Testing performed.
ZUPRKP	Our lab does not currently have a confirmatory method for benzoylecgonine.

Additional Test Comments

TABLE 4

WebCode	Additional Comments
44YQHG	Original analysis completed by [Name]. Report completed by [Name].
727GLK	Date reflects the date the PT arrived at the laboratory and COC started.
76GRCU	Sample arrived in my lab on 10/15/2020 and I took possession of the samples 11/03/2020. I performed screen analysis 11/04/2020 and confirmatory analysis 11/05/2020.
8EL42W	All the samples were only screened using immunoassay techniques with preloaded tests consisted of MAMP, BARB, BENZ, MDONE, OPIAT, PCP, BZG, MDMA, THC, TCA, AMPH and BUP.
DQLF7C	Our lab can currently only quantitate and confirm THC-OH, THC, THC-COOH, Amphetamine, Methamphetamine, Ketamine, Mescaline, MDA, MDMA, Phentermine, LSD, Diphenhydramine, Psilocin, Ephedrine/Pseudoephedrine.
DVT9XM	I took custody of the sample on 11/06/2020.
EBNQP7	Caffeine was present in all 3 samples: Item 1, 2 and 3.
KB6TY2	Hexobarbital and Phenyltoloxamine were added as internal reference materials.
LG7QMW	Caffeine may have been present in the samples, but our lab does not report caffeine at this time.
RJRLQQ	Caffeine may have been present in the samples, but our lab does not report caffeine at this time.
T9PLQQ	Only sample 2 was analysed as we are using CTS trial for the purposes of Road Traffic Offences.
V6X936	reported results obtained from pre-distribution test.
VLAMK3	All samples appeared to contain Naproxen, Caffeine and Theophylline. They were detected in three items. They could be artifact and therefore, these drugs were not listed in the result sheets.
Z8QNGW	Cocaine has known stability issues. I would anticipate some varied results for labs depending on shipment times and testing dates.
ZMZJU6	Only Screening Testing performed.

-End of Report-
(Appendix may follow)

Collaborative Testing Services ~ Forensic Testing Program

Test No. 20-5661: Blood Drug Analysis

DATA MUST BE SUBMITTED BY **Nov. 30, 2020, 11:59 p.m.** TO BE INCLUDED IN THE REPORT

Participant Code: U1234D WebCode: 26L9VC

Scenario:

Investigators have submitted two vials of blood from each of three separate cases for your analysis. Using your laboratory's procedures, analyze each item and report the presence of any drugs and/or metabolites.

Case 1: A 71 year-old female was found unresponsive one morning by her daughter. The daughter mentioned that her mother was recently widowed and as a result, was feeling anxious and not sleeping well. Blood samples were collected at autopsy.

Case 2: A 28 year-old male was pulled over for a broken tail light. The officer noticed that the driver appeared drowsy and lethargic. A Drug Recognition Expert arrived and noted that the individual exhibited ataxia and loss of coordination. The result of a breath alcohol test was 0.00%. Blood was collected 60 minutes later.

Case 3: A 45 year-old male was involved in a bar fight. He was taken to the hospital for injuries where it was noted that his blood pressure was elevated and his pupils were dilated. He was also exhibiting aggressive behavior. Blood samples were collected at the hospital.

-Samples may contain methanol and acetonitrile as artifacts from production.

***PLEASE NOTE** The purpose of this test is the examination of drugs listed in section 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act that fall into the following classes: benzodiazepines, nonbenzodiazepine hypnotics (z-drugs), barbiturates, opioids, illicit hallucinogens, illicit stimulants, illicit depressants, and cannabinoids. Please test accordingly.*

Items Submitted (Sample Pack BDRG):

Item 1: Two vials of blood from Case 1
Item 2: Two vials of blood from Case 2
Item 3: Two vials of blood from Case 3

Test No. 20-5661 Data Sheet, continued

Participant Code: U1234D
WebCode: 26L9VC

Screening Results for Item 1:

1-1). Please indicate the screening results for Item 1.

- ○ No drugs detected utilizing screening methods.
- ○ Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 1:

1-2). What drugs/metabolites were detected in Item 1? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

1-3). If quantitative analysis was performed, are the reported concentrations above

- ○ A single determination?
- ○ The mean of duplicate / several determinations?
- ○ Other? (Specify):

1-4). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

1-5). Additional Comments for Item 1

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

Test No. 20-5661 Data Sheet, continued

Participant Code: U1234D
WebCode: 26L9VC

Screening Results for Item 2:

2-1). Please indicate the screening results for Item 2.

- ○ No drugs detected utilizing screening methods.
- ○ Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 2:

2-2). What drugs/metabolites were detected in Item 2? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

2-3). If quantitative analysis was performed, are the reported concentrations above

- ○ A single determination?
- ○ The mean of duplicate / several determinations?
- ○ Other? (Specify):

2-4). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

2-5). Additional Comments for Item 2

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

Test No. 20-5661 Data Sheet, continued

Participant Code: U1234D
WebCode: 26L9VC

Screening Results for Item 3:

3-1). Please indicate the screening results for Item 3.

- ○ No drugs detected utilizing screening methods.
- ○ Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 3:

3-2). What drugs/metabolites were detected in Item 3? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

3-3). If quantitative analysis was performed, are the reported concentrations above

- ○ A single determination?
- ○ The mean of duplicate / several determinations?
- ○ Other? (Specify):

3-4). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

3-5). Additional Comments for Item 3

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

Test No. 20-5661 Data Sheet, continued

Participant Code: U1234D
WebCode: 26L9VC

Date Samples Received:

Additional Comments on Test

Please note: *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

Test No. 20-5661 Data Sheet, continued

Participant Code: U1234D
WebCode: 26L9VC

RELEASE OF DATA TO ACCREDITATION BODIES

The Accreditation Release is accessed by pressing the "Continue to Final Submission" button online and can be completed at any time prior to submission to CTS.

CTS submits external proficiency test data directly to ASCLD/LAB, ANAB, and/or A2LA. Please select one of the following statements to ensure your data is handled appropriately.

○ This participant's data is intended for submission to ASCLD/LAB, ANAB, and/or A2LA. (Accreditation Release section below must be completed.)
○ This participant's data is **not** intended for submission to ASCLD/LAB, ANAB, and/or A2LA.

Have the laboratory's designated individual complete the following steps
only if your laboratory is accredited in this testing/calibration discipline
by one or more of the following Accreditation Bodies.

Step 1: Provide the applicable Accreditation Certificate Number(s) for your laboratory

ANAB Certificate No.
(Include ASCLD/LAB Certificate here)

A2LA Certificate No.

Step 2: Complete the Laboratory Identifying Information in its entirety

Authorized Contact Person and Title

Laboratory Name

Location (City/State)